<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Stem cell‐based interventions for the prevention and treatment of intraventricular haemorrhage and encephalopathy of prematurity in preterm infants - Romantsik, O - 2023 | Cochrane Library</title> <meta content="Stem cell‐based interventions for the prevention and treatment of intraventricular haemorrhage and encephalopathy of prematurity in preterm infants - Romantsik, O - 2023 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013201.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Stem cell‐based interventions for the prevention and treatment of intraventricular haemorrhage and encephalopathy of prematurity in preterm infants - Romantsik, O - 2023 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013201.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013201.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Stem cell‐based interventions for the prevention and treatment of intraventricular haemorrhage and encephalopathy of prematurity in preterm infants" name="citation_title"/> <meta content="Olga Romantsik" name="citation_author"/> <meta content="Lund University, Skåne University Hospital" name="citation_author_institution"/> <meta content="Alvaro Moreira" name="citation_author"/> <meta content="University of Texas Health Science Center at San Antonio" name="citation_author_institution"/> <meta content="Bernard Thébaud" name="citation_author"/> <meta content="Ulrika Ådén" name="citation_author"/> <meta content="Karolinska Institutet" name="citation_author_institution"/> <meta content="David Ley" name="citation_author"/> <meta content="Lund University, Skåne University Hospital" name="citation_author_institution"/> <meta content="Matteo Bruschettini" name="citation_author"/> <meta content="matteo.bruschettini@med.lu.se" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD013201.pub3" name="citation_doi"/> <meta content="2023" name="citation_date"/> <meta content="2023/02/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013201.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013201.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013201.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Cerebral Hemorrhage [prevention &amp; control]; Infant Mortality; Infant, Extremely Premature; *Infant, Premature, Diseases [etiology, prevention &amp; control]; Stem Cells" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013201.pub3&amp;doi=10.1002/14651858.CD013201.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013201.pub3&amp;doi=10.1002/14651858.CD013201.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013201.pub3&amp;doi=10.1002/14651858.CD013201.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013201.pub3&amp;doi=10.1002/14651858.CD013201.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013201.pub3&amp;doi=10.1002/14651858.CD013201.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013201.pub3&amp;doi=10.1002/14651858.CD013201.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013201.pub3&amp;doi=10.1002/14651858.CD013201.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013201.pub3&amp;doi=10.1002/14651858.CD013201.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013201.pub3&amp;doi=10.1002/14651858.CD013201.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013201.pub3&amp;doi=10.1002/14651858.CD013201.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013201.pub3&amp;doi=10.1002/14651858.CD013201.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013201.pub3&amp;doi=10.1002/14651858.CD013201.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013201.pub3&amp;doi=10.1002/14651858.CD013201.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013201.pub3&amp;doi=10.1002/14651858.CD013201.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013201.pub3&amp;doi=10.1002/14651858.CD013201.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013201.pub3&amp;doi=10.1002/14651858.CD013201.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013201.pub3&amp;doi=10.1002/14651858.CD013201.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013201.pub3&amp;doi=10.1002/14651858.CD013201.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013201.pub3&amp;doi=10.1002/14651858.CD013201.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013201.pub3&amp;doi=10.1002/14651858.CD013201.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013201.pub3&amp;doi=10.1002/14651858.CD013201.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013201.pub3&amp;doi=10.1002/14651858.CD013201.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013201.pub3&amp;doi=10.1002/14651858.CD013201.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="BqmVIxTs";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013201\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013201\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013201\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013201\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ko","th","ms","fa","id","pl","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013201.pub3",title:"Stem cell\\u2010based interventions for the prevention and treatment of intraventricular haemorrhage and encephalopathy of prematurity in preterm infants",firstPublishedDate:"Feb 15, 2023 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neonatal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013201.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013201.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013201.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013201.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013201.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013201.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013201.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013201.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013201.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013201.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;id&quot;,&quot;title&quot;:&quot;Saripati tinjauan sistematik&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013201.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013201.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013201.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013201.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1934 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013201.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013201.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013201.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013201.pub3/full#CD013201-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013201.pub3/full#CD013201-sec-0063"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013201.pub3/full#CD013201-sec-0008"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013201.pub3/full#CD013201-sec-0018"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013201.pub3/full#CD013201-sec-0019"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013201.pub3/full#CD013201-sec-0043"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013201.pub3/full#CD013201-sec-0057"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013201.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013201.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013201.pub3/appendices#CD013201-sec-0067"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013201.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013201.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013201.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013201.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013201.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013201.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013201.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2023 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013201.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Stem cell‐based interventions for the prevention and treatment of intraventricular haemorrhage and encephalopathy of prematurity in preterm infants </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013201.pub3/information#CD013201-cr-0004">Olga Romantsik</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013201.pub3/information#CD013201-cr-0005">Alvaro Moreira</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013201.pub3/information#CD013201-cr-0006">Bernard Thébaud</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013201.pub3/information#CD013201-cr-0007">Ulrika Ådén</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013201.pub3/information#CD013201-cr-0008">David Ley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013201.pub3/information#CD013201-cr-0009"><i class="icon corresponding-author fa fa-envelope"></i>Matteo Bruschettini</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013201.pub3/information/en#CD013201-sec-0081">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 February 2023 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013201.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013201.pub3">https://doi.org/10.1002/14651858.CD013201.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013201-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013201-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013201-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013201-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013201-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013201-abs-0004">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD013201-abs-0006">ภาษาไทย</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013201-abs-0001" lang="en"> <section id="CD013201-sec-0001"> <h3 class="title" id="CD013201-sec-0001">Background</h3> <p>Germinal matrix‐intraventricular haemorrhage (GMH‐IVH) and encephalopathy of prematurity (EoP) remain substantial issues in neonatal intensive care units worldwide. Current therapies to prevent or treat these conditions are limited. Stem cell‐based therapies offer a potential therapeutic approach to repair, restore, or regenerate injured brain tissue. These preclinical findings have now culminated in ongoing human neonatal studies. This is an update of the 2019 review, which did not include EoP. </p> </section> <section id="CD013201-sec-0002"> <h3 class="title" id="CD013201-sec-0002">Objectives</h3> <p>To evaluate the benefits and harms of stem cell‐based interventions for prevention or treatment of GM‐IVH and EoP in preterm infants. </p> </section> <section id="CD013201-sec-0003"> <h3 class="title" id="CD013201-sec-0003">Search methods</h3> <p>We used standard, extensive Cochrane search methods. The latest search was April 2022.</p> </section> <section id="CD013201-sec-0004"> <h3 class="title" id="CD013201-sec-0004">Selection criteria</h3> <p>We attempted to include randomised controlled trials, quasi‐randomised controlled trials, and cluster trials comparing 1. stem cell‐based interventions versus control; 2. mesenchymal stromal cells (MSCs) of type or source versus MSCs of other type or source; 3. stem cell‐based interventions other than MSCs of type or source versus stem cell‐based interventions other than MSCs of other type or source; or 4. MSCs versus stem cell‐based interventions other than MSCs. For prevention studies, we included extremely preterm infants (less than 28 weeks' gestation), 24 hours of age or less, without ultrasound diagnosis of GM‐IVH or EoP; for treatment studies, we included preterm infants (less than 37 weeks' gestation), of any postnatal age, with ultrasound diagnosis of GM‐IVH or with EoP. </p> </section> <section id="CD013201-sec-0005"> <h3 class="title" id="CD013201-sec-0005">Data collection and analysis</h3> <p>We used standard Cochrane methods. Our primary outcomes were 1. all‐cause neonatal mortality, 2. major neurodevelopmental disability, 3. GM‐IVH, 4. EoP, and 5. extension of pre‐existing non‐severe GM‐IVH or EoP. We planned to use GRADE to assess certainty of evidence for each outcome. </p> </section> <section id="CD013201-sec-0006"> <h3 class="title" id="CD013201-sec-0006">Main results</h3> <p>We identified no studies that met our inclusion criteria. Three studies are currently registered and ongoing. Phase 1 trials are described in the 'Excluded studies' section. </p> </section> <section id="CD013201-sec-0007"> <h3 class="title" id="CD013201-sec-0007">Authors' conclusions</h3> <p>No evidence is currently available to evaluate the benefits and harms of stem cell‐based interventions for treatment or prevention of GM‐IVH or EoP in preterm infants. We identified three ongoing studies, with a sample size range from 20 to 200. In two studies, autologous cord blood mononuclear cells will be administered to extremely preterm infants via the intravenous route; in one, intracerebroventricular injection of MSCs will be administered to preterm infants up to 34 weeks' gestational age. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013201-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013201-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013201-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013201-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013201-abs-0014">Français</a> </li> <li class="section-language"> <a class="" href="full/id#CD013201-abs-0011">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="full/ko#CD013201-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013201-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD013201-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/th#CD013201-abs-0007">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013201-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013201-abs-0002" lang="en"> <h3>Stem cell‐based therapies for brain injury in newborns born preterm</h3> <p><b>Review question</b> </p> <p>Do stem cell‐based therapies save the lives or improve the long‐term development of preterm newborns who have or may develop bleeding to the brain (intraventricular haemorrhage) or grey matter damage? </p> <p><b>Background</b> </p> <p>Newborns born too early ('preterm'), especially babies born before 28 weeks of pregnancy, sometimes develop bleeding to the brain. Babies with less severe bleeding may make a full recovery or may have only mild problems. For other babies with more serious bleeding, or with grey matter damage, this may lead to death or to problems later in life. The brain is growing very fast during the second and third trimester of pregnancy. Nerve cells move throughout the brain to destination regions, where they become mature and make connections with each other in order to proceed with the information. In addition, some nerve fibres are surrounded by a specific insulating layer, called myelin, and the process of such insulation – myelinisation – starts around 24 weeks of pregnancy. If the baby is born preterm these processes in the brain may be altered and there is a higher risk for long‐term abnormal neurodevelopment. This condition is called 'encephalopathy of prematurity'. For instance, some of these babies develop intellectual disabilities, behavioural problems, concentration difficulties, socialisation problems, and cerebral palsy. Currently, no approaches are available to prevent or treat bleeding to the brain or grey matter damage. </p> <p><b>What did we want to find out?</b> </p> <p>The aim of this review was to assess whether stem cell‐based therapies could reduce death and improve the long‐term development of newborns born too early. During cell stem‐based therapy, stem cells are given to the baby, for instance, through injection. These stem cells may have come from humans or animals and may have been taken from cord blood, bone marrow, or other parts of the body. These cells then repair the brain cells that have been damaged by bleeding or grey matter damage. </p> <p><b>What did we do?</b> </p> <p>We searched medical databases for clinical trials looking at stem cell‐based therapies for brain injury in newborns born too soon. </p> <p><b>Key results</b> </p> <p>We were unable to include any studies in our review. We did identify nine studies, but we excluded them because of the way they were designed, which meant that their results could not answer our review question. </p> <p><b>How current is the evidence?</b> </p> <p>This review updates and expands our previous review which was published in 2019. The evidence is current to April 2022. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013201-sec-0063" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013201-sec-0063"></div> <h3 class="title" id="CD013201-sec-0064">Implications for practice</h3> <section id="CD013201-sec-0064"> <p>No evidence is currently available to evaluate the benefits and harms of stem cell‐based interventions for treatment or prevention of germinal matrix‐intraventricular haemorrhage (GM‐IVH) or encephalopathy of prematurity (EoP) in preterm infants. We identified three ongoing studies, with a sample size range of 20 to 200. In two studies, autologous cord blood mononuclear cells will be administered to extremely preterm infants via the intravenous route; in one, intracerebroventricular injection of MSCs will be administered to preterm infants up to 34 weeks' gestational age. </p> </section> <h3 class="title" id="CD013201-sec-0065">Implications for research</h3> <section id="CD013201-sec-0065"> <p>Future challenges in summarising data on regenerative cells for neonates with, or at risk for, GM‐IVH or EoP can be divided into four central themes. </p> <p> <ul id="CD013201-list-0033"> <li> <p><b>Cell therapy:</b> does cell therapy provide therapeutic benefit? Which cell and tissue source confers efficacy? What dose and route of delivery optimises benefit? How frequently should therapy be administered? Is there synergism when more than one cell therapy is used? </p> </li> <li> <p><b>Patient selection:</b> which patients should be treated? When should they be treated (i.e. preventive or rescue)? Does sex or ethnicity (or both) impact therapeutic potential? </p> </li> <li> <p><b>Cell processing:</b> should cells be used fresh, or can they be frozen and thawed? What viability of cells is acceptable for transplantation? How many passages of the cells are tolerable? Which assay(s) deliver the best in vivo results? What is/are the mechanisms by which regenerative cells work for neonatal brain injury? </p> </li> <li> <p><b>Outcome measure:</b> should the focus be on prevention of intraventricular haemorrhage/EoP or progression of disease? On functional outcome or imaging studies? Or on a combined outcome of death or ventriculoperitoneal surgical intervention? </p> </li> </ul> </p> <p>Ideally, these questions ought to be addressed in rigorous preclinical studies to guide the design of human studies. Focusing on answering these questions may prevent large, costly, labour‐intense human studies that may result in variable results. In summary, optimising regenerative cells in small and large animals will provide the groundwork for future clinical trials. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013201-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013201-sec-0008"></div> <section id="CD013201-sec-0009"> <h3 class="title" id="CD013201-sec-0009">Description of the condition</h3> <section id="CD013201-sec-0010"> <h4 class="title">Neonatal brain injury</h4> <p>Neonatal brain injury in preterm infants includes germinal matrix‐intraventricular haemorrhage (GMH‐IVH) and encephalopathy of prematurity (EoP), which are discussed below. </p> <section id="CD013201-sec-0011"> <h5 class="title">Germinal matrix‐intraventricular haemorrhage</h5> <p>Preterm birth remains the major risk factor for developing GMH‐IVH. GMH‐IVH occurs in 25% of very low birth weight (VLBW) infants (<a href="./references#CD013201-bbs2-0115" title="NCT01825499. Vermont Oxford Network very low birth weight database (VON VLBW). clinicaltrials.gov/ct2/show/NCT01825499 (first received 5 April 2013).">NCT01825499</a>), and complications of GMH‐IVH, including periventricular haemorrhagic infarction, posthaemorrhagic ventricular dilation (PHVD), cerebellar haemorrhagic injury, and periventricular leukomalacia (PVL), affect neonatal morbidity, mortality, and long‐term neurodevelopmental outcomes (<a href="./references#CD013201-bbs2-0162" title="SherlockRL , AndersonPJ , DoyleLW , Victorian Infant Collaborative Study Group. Neurodevelopmental sequelae of intraventricular haemorrhage at 8 years of age in a regional cohort of ELBW/very preterm infants. Early Human Development2005;81(11):909-16. [DOI: 10.1016/j.earlhumdev.2005.07.007] [PMID: 16126353]">Sherlock 2005</a>). </p> <p>Although improvements in perinatal care since the late 1970s have led to significant reduction in the incidence of GMH‐IVH in preterm infants (from 50% in the late 1970s to current rates of 15% to 25%) (<a href="./references#CD013201-bbs2-0068" title="HamrickSE , MillerSP , LeonardC , GliddenDV , GoldsteinR , RamaswamyV , et al. Trends in severe brain injury and neurodevelopmental outcome in premature newborn infants: the role of cystic periventricular leukomalacia. Journal of Pediatrics2004;145(5):593-9. [DOI: 10.1016/j.jpeds.2004.05.042] [PMID: 15520756]">Hamrick 2004</a>; <a href="./references#CD013201-bbs2-0073" title="HorbarJD , BadgerGJ , CarpenterJH , FanaroffAA , KilpatrickS , LaCorteM , et al, Members of the Vermont Oxford Network. Trends in mortality and morbidity for very low birth weight infants, 1991–1999. Pediatrics2002;110(1 Pt 1):143-51. [PMID: 12093960]">Horbar 2002</a>; <a href="./references#CD013201-bbs2-0142" title="PhilipAG , AllanWC , TitoAM , WheelerLR . Intraventricular hemorrhage in preterm infants: declining incidence in the 1980s. Pediatrics1989;84(5):797-801. [PMID: 2677959]">Philip 1989</a>), GMH‐IVH remains a substantial issue in neonatal intensive care units worldwide. Survival of extremely preterm infants has increased drastically to as high as 85% to 90% (<a href="./references#CD013201-bbs2-0056" title="FellmanV , Hellström-WestasL , NormanM , WestgrenM , KällénK , LagercrantzH , et al, EXPRESS Group. One-year survival of extremely preterm infants after active perinatal care in Sweden. JAMA2009;301(21):2225-33. [DOI: 10.1001/jama.2009.771] [PMID: 19491184]">EXPRESS 2009</a>; <a href="./references#CD013201-bbs2-0079" title="IshiiN , KonoY , YonemotoN , KusudaS , FujimuraM , Neonatal Research Network, Japan. Outcomes of infants born at 22 and 23 weeks' gestation. Pediatrics2013;132(1):62-71. [DOI: 10.1542/peds.2012-2857] [PMID: 23733804]">Ishii 2013</a>). Moreover, the survival rate of preterm infants at the lower gestational age, who are highly susceptible for the development of GMH‐IVH and its sequelae, has increased notably since the late 1970s. Approximately 45% of preterm infants with birth weight below 750 g are affected by some degree of GMH‐IVH, and up to 35% of these haemorrhages are categorised as severe (<a href="./references#CD013201-bbs2-0191" title="Wilson-CostelloD , FriedmanH , MinichN , FanaroffAA , HackM . Improved survival rates with increased neurodevelopmental disability for extremely low birth weight infants in the 1990s. Pediatrics2005;115(4):997-1003. [DOI: 10.1542/peds.2004-0221] [PMID: 15805376]">Wilson‐Costello 2005</a>). Thus, it seems that we have observed a plateau in the incidence of GMH‐IVH (<a href="./references#CD013201-bbs2-0073" title="HorbarJD , BadgerGJ , CarpenterJH , FanaroffAA , KilpatrickS , LaCorteM , et al, Members of the Vermont Oxford Network. Trends in mortality and morbidity for very low birth weight infants, 1991–1999. Pediatrics2002;110(1 Pt 1):143-51. [PMID: 12093960]">Horbar 2002</a>; <a href="./references#CD013201-bbs2-0074" title="HorbarJD , CarpenterJH , BadgerGJ , KennyMJ , SollRF , MorrowKA , et al. Mortality and neonatal morbidity among infants 501 to 1500 grams from 2000 to 2009. Pediatrics2012;129(6):1019-26. [DOI: 10.1542/peds.2011-3028] [PMID: 22614775]">Horbar 2012</a>). Approximately 50% to 75% of preterm survivors with GM‐IVH (any grade) develop cerebral palsy, cognitive impairment, PHVD, or a combination of these conditions, with serious sequelae for neurodevelopmental outcomes (<a href="./references#CD013201-bbs2-0100" title="LuuTM , MentLR , SchneiderKC , KatzKH , AllanWC , VohrBR . Lasting effects of preterm birth and neonatal brain hemorrhage at 12 years of age. Pediatrics2009;123(3):1037-44. [DOI: 10.1542/peds.2008-1162] [PMID: 19255037]">Luu 2009</a>). Moreover, around 25% of non‐disabled survivors develop psychiatric disorders and problems with executive function (<a href="./references#CD013201-bbs2-0078" title="IndredavikMS , VikT , EvensenKA , SkranesJ , TaraldsenG , BrubakkAM . Perinatal risk and psychiatric outcome in adolescents born preterm with very low birth weight or term small for gestational age. Journal of Developmental and Behavioral Pediatrics2010;31(4):286-94. [DOI: 10.1097/DBP.0b013e3181d7b1d3] [PMID: 20431402]">Indredavik 2010</a>; <a href="./references#CD013201-bbs2-0126" title="NosartiC , GiouroukouE , MicaliN , RifkinL , MorrisRG , MurrayRM . Impaired executive functioning in young adults born very preterm. JINS2007;13(4):571-81. [DOI: 10.1017/S1355617707070725] [PMID: 17521479]">Nosarti 2007</a>; <a href="./references#CD013201-bbs2-0190" title="WhitakerAH , FeldmanJF , LorenzJM , McNicholasF , FisherPW , ShenS , et al. Neonatal head ultrasound abnormalities in preterm infants and adolescent psychiatric disorders. Archives of General Psychiatry2011;68(7):742-52. [DOI: 10.1001/archgenpsychiatry.2011.62] [PMID: 21727256]">Whitaker 2011</a>). Hence, GMH‐IVH as well as its neurological and psychiatric consequences continues to be a noteworthy public health concern worldwide. </p> <p>In general, the diagnosis of GMH‐IVH is made during the first week of life; approximately 50% of these haemorrhages are seen during the first 24 hours of life, and as much as 90% of GMH‐IVH is diagnosed within the first 96 hours of life. Up to 40% of these bleeds will increase in size during the first days of life (<a href="./references#CD013201-bbs2-0183" title="VolpeJV . Neurology of the Newborn. 5th edition. Philadelphia (PA): Saunders, 2008.">Volpe 2008</a>). The incidence of antenatal GM‐IVH is unclear, although an estimate for intracranial bleeding of 1 in 10,000 pregnancies has been suggested (<a href="./references#CD013201-bbs2-0180" title="VerganiP , StrobeltN , LocatelliA , PaterliniG , TagliabueP , ParraviciniE , et al. Clinical significance of fetal intracranial hemorrhage. American Journal of Obstetrics and Gynecology1996;175(3 Pt 1):536-43. [PMID: 8928712]">Vergani 1996</a>). Antenatal foetal intracranial haemorrhage may occur spontaneously or in association with various maternal or foetal conditions. Predisposing maternal conditions include platelet and coagulation disorders, medications (warfarin), illicit drugs (cocaine), seizures, smoking, trauma, amniocentesis, and febrile disease; foetal conditions include twin–twin transfusion, demise of a co‐twin, hydrops fetalis, congenital tumour, and fetomaternal haemorrhage (<a href="./references#CD013201-bbs2-0091" title="KutukMS , YikilmazA , OzgunMT , DolanbayM , CanpolatM , UludagS , et al. Prenatal diagnosis and postnatal outcome of fetal intracranial hemorrhage. Child's Nervous System2014;30(3):411-8. [DOI: 10.1007/s00381-013-2243-0] [PMID: 23907139]">Kutuk 2014</a>). GM‐IVH may undergo spontaneous resolution or, especially for grade 3 and 4, may lead to development of PHVD. </p> <section id="CD013201-sec-0012"> <h6 class="title">Pathophysiology of germinal matrix‐intraventricular haemorrhage</h6> <p>Both low‐grade and high‐grade GMH‐IVH may affect cerebellar growth, resulting in reduced cerebellar volume and impaired white matter and motor tract microstructure (<a href="./references#CD013201-bbs2-0109" title="MoritaT , MorimotoM , YamadaK , HasegawaT , MoriokaS , KidowakiS , et al. Low-grade intraventricular hemorrhage disrupts cerebellar white matter in preterm infants: evidence from diffusion tensor imaging. Neuroradiology2015;57(5):507-14. [DOI: 10.1007/s00234-015-1487-7] [PMID: 25596864]">Morita 2015</a>; <a href="./references#CD013201-bbs2-0156" title="SancakS , GursoyT , ImamogluEY , KaratekinG , OvaliF . Effect of prematurity on cerebellar growth. Journal of Child Neurology2016;31(2):138-44. [DOI: 10.1177/0883073815585350] [PMID: 25971263]">Sancak 2016</a>; <a href="./references#CD013201-bbs2-0157" title="SancakS , GursoyT , KaratekinG , OvaliF . Effect of intraventricular hemorrhage on cerebellar growth in preterm neonates. Cerebellum2017;16(1):89-94. [DOI: 10.1007/s12311-016-0766-0] [PMID: 26924821]">Sancak 2017</a>; <a href="./references#CD013201-bbs2-0164" title="SrinivasanL , AllsopJ , CounsellSJ , BoardmanJP , EdwardsAD , RutherfordM . Smaller cerebellar volumes in very preterm infants at term-equivalent age are associated with the presence of supratentorial lesions. AJNR. American Journal of Neuroradiology2006;27(3):573-9. [PMID: 16551994]">Srinivasan 2006</a>; <a href="./references#CD013201-bbs2-0168" title="TamEW , FerrieroDM , XuD , BermanJI , VigneronDB , BarkovichAJ , et al. Cerebellar development in the preterm neonate: effect of supratentorial brain injury. Pediatric Research2009;66(1):102-6. [DOI: 10.1203/PDR.0b013e3181a1fb3d] [PMID: 19287350]">Tam 2009</a>; <a href="./references#CD013201-bbs2-0169" title="TamEW , MillerSP , StudholmeC , ChauV , GliddenD , PoskittKJ , et al. Differential effects of intraventricular hemorrhage and white matter injury on preterm cerebellar growth. Journal of Pediatrics2011;158(3):366-71. [DOI: 10.1016/j.jpeds.2010.09.005] [PMID: 20961562]">Tam 2011</a>). The cerebellum is the fastest‐growing portion of the brain; its volume increases fivefold from 24 weeks' postmenstrual age to 40 weeks' postmenstrual age (<a href="./references#CD013201-bbs2-0184" title="VolpeJJ . Cerebellum of the premature infant: rapidly developing, vulnerable, clinically important. Journal of Child Neurology2009;24(9):1085-104. [DOI: 10.1177/0883073809338067] [PMID: 19745085]">Volpe 2009a</a>). During this period, extravasation of haemoglobin due to GMH‐IVH into cerebrospinal fluid and further haemolysis of free haemoglobin may result in deposition of haemosiderin on the cerebellar surface, disturbing normal development of the cerebellar cortex (<a href="./references#CD013201-bbs2-0013" title="AgyemangAA , SveinsdóttirK , ValliusS , SveinsdóttirS , BruschettiniM , RomantsikO , et al. Cerebellar exposure to cell-free hemoglobin following preterm intraventricular hemorrhage: causal in cerebellar damage?Translational Stroke Research2017;8(5):461-73. [DOI: 10.1007/s12975-017-0539-1] [PMID: 28601919]">Agyemang 2017</a>; <a href="./references#CD013201-bbs2-0060" title="FukumizuM , TakashimaS , BeckerLE . Neonatal posthemorrhagic hydrocephalus: neuropathologic and immunohistochemical studies. Pediatric Neurology1995;13(3):230-4. [PMID: 8554660]">Fukumizu 1995</a>; <a href="./references#CD013201-bbs2-0090" title="KoeppenAH , MichaelSC , LiD , ChenZ , CusackMJ , GibsonWM , et al. The pathology of superficial siderosis of the central nervous system. Acta Neuropathologica2008;116(4):371-82. [DOI: 10.1007/s00401-008-0421-z] [PMID: 18696091]">Koeppen 2008</a>; <a href="./references#CD013201-bbs2-0105" title="MesserschmidtA , BruggerPC , BoltshauserE , ZoderG , SternisteW , BirnbacherR , et al. Disruption of cerebellar development: potential complication of extreme prematurity. AJNR. American Journal of Neuroradiology2005;26(7):1659-67. [PMID: 16091510]">Messerschmidt 2005</a>). It is well recognised that the cerebellum plays a crucial role not only in motor function but also in many higher‐order cognitive and affective functions, such as executive function, working memory, and emotional processing (<a href="./references#CD013201-bbs2-0178" title="vanOverwalleF , BaetensK , MariënP , VandekerckhoveM . Social cognition and the cerebellum: a meta-analysis of over 350 fMRI studies. Neuroimage2014;86:554-72. [DOI: 10.1016/j.neuroimage.2013.09.033] [PMID: 24076206]">van Overwalle 2014</a>; <a href="./references#CD013201-bbs2-0184" title="VolpeJJ . Cerebellum of the premature infant: rapidly developing, vulnerable, clinically important. Journal of Child Neurology2009;24(9):1085-104. [DOI: 10.1177/0883073809338067] [PMID: 19745085]">Volpe 2009a</a>). Thus, preventing GMH‐IVH would also help to preserve cerebellar integrity. </p> <p>The aetiology of GMH‐IVH is multifactorial, complex, and heterogeneous (<a href="./references#CD013201-bbs2-0151" title="RomantsikO , BruschettiniM , LeyD . Intraventricular hemorrhage and white matter injury in preclinical and clinical studies. NeoReviews2019;20(11):e636-52. [PMID: 31676738]">Romantsik 2019a</a>). An intrinsic fragility of the germinal matrix (GM) vasculature predisposes patients to haemorrhage, and fluctuation in cerebral blood flow (CBF) induces the rupture of vasculature (<a href="./references#CD013201-bbs2-0024" title="BallabhP . Pathogenesis and prevention of intraventricular hemorrhage. Clinics in Perinatology2014;41(1):47-67. [DOI: 10.1016/j.clp.2013.09.007] [PMID: 24524446]">Ballabh 2014</a>). The association between CBF fluctuation and onset of GM‐IVH in ventilated neonates with respiratory distress syndrome (RDS) during the first day of life was suggested by Perlman and colleagues (<a href="./references#CD013201-bbs2-0139" title="PerlmanJM , McMenaminJB , VolpeJJ . Fluctuating cerebral blood-flow velocity in respiratory-distress syndrome. Relation to the development of intraventricular hemorrhage. New England Journal of Medicine1983;309(4):204-9. [DOI: 10.1056/NEJM198307283090402] [PMID: 6866033]">Perlman 1983</a>). One subsequent study by the same group showed that elimination of CBF fluctuation by neuromuscular paralysis (pancuronium) resulted in reduction in GM‐IVH (<a href="./references#CD013201-bbs2-0140" title="PerlmanJM , GoodmanS , KreusserKL , VolpeJJ . Reduction in intraventricular hemorrhage by elimination of fluctuating cerebral blood-flow velocity in preterm infants with respiratory distress syndrome. New England Journal of Medicine1985;312(21):1353-7. [DOI: 10.1056/NEJM198505233122104] [PMID: 3887165]">Perlman 1985</a>). The question remained whether the fluctuations in CBF were due to breathing against the ventilator, which could be explained by increased pleural pressure fluctuations. Two studies confirmed that CBF fluctuations were related to RDS extent and pleural pressure fluctuations, and that those could be damped by mechanical ventilation (<a href="./references#CD013201-bbs2-0112" title="MullaartRA , HopmanJC , RotteveelJJ , DanielsO , StoelingaGB , De HaanAF . Cerebral blood flow fluctuation in neonatal respiratory distress and periventricular haemorrhage. Early Human Development1994;37(3):179-85. [PMID: 7925076]">Mullaart 1994</a>; <a href="./references#CD013201-bbs2-0141" title="PerlmanJ , ThachB . Respiratory origin of fluctuations in arterial blood pressure in premature infants with respiratory distress syndrome. Pediatrics1988;81(3):399-403. [PMID: 3344182]">Perlman 1988</a>). It has been suggested that loss of cerebral autoregulation, which is important for maintaining constant CBF, may predispose preterm infants to haemorrhagic and ischaemic cerebral injury (<a href="./references#CD013201-bbs2-0035" title="BoylanGB , YoungK , PaneraiRB , RennieJM , EvansDH . Dynamic cerebral autoregulation in sick newborn infants. Pediatric Research2000;48(1):12-7. [DOI: 10.1203/00006450-200007000-00005] [PMID: 10879794]">Boylan 2000</a>; <a href="./references#CD013201-bbs2-0173" title="TsujiM , duPlessisA , TaylorG , CrockerR , VolpeJJ . Near infrared spectroscopy detects cerebral ischemia during hypotension in piglets. Pediatric Research1998;44(4):591-5. [DOI: 10.1203/00006450-199810000-00020] [PMID: 9773851]">Tsuji 1998</a>). However, ensuing studies on impaired autoregulation were not predictive of the subsequent development of GM‐IVH; nevertheless impaired autoregulation was correlated with higher mortality (<a href="./references#CD013201-bbs2-0163" title="SoulJS , HammerPE , TsujiM , SaulJP , BassanH , LimperopoulosC , et al. Fluctuating pressure-passivity is common in the cerebral circulation of sick premature infants. Pediatric Research2007;61(4):467-73. [DOI: 10.1203/pdr.0b013e31803237f6] [PMID: 17515873]">Soul 2007</a>; <a href="./references#CD013201-bbs2-0192" title="WongFY , LeungTS , AustinT , WilkinsonM , MeekJH , WyattJS , et al. Impaired autoregulation in preterm infants identified by using spatially resolved spectroscopy. Pediatrics2008;121(3):e604-11. [DOI: 10.1542/peds.2007-1487] [PMID: 18250118]">Wong 2008</a>). Vaginal delivery, low Apgar score, severe RDS, pneumothorax, hypoxia, hypercapnia, seizures, patent ductus arteriosus, infection, and other conditions seem to increase primarily the fluctuations in CBF, and thus represent important risk factors for development of GM‐IVH (<a href="./references#CD013201-bbs2-0024" title="BallabhP . Pathogenesis and prevention of intraventricular hemorrhage. Clinics in Perinatology2014;41(1):47-67. [DOI: 10.1016/j.clp.2013.09.007] [PMID: 24524446]">Ballabh 2014</a>). If platelet or coagulation disorders are associated, the homeostasis mechanisms are impaired, which might accentuate the haemorrhage. The GM is located inside an arterial end zone, resulting in a direct interconnection with the deep galenic venous system of the brain (<a href="./references#CD013201-bbs2-0114" title="NakamuraY , OkuderaT , FukudaS , HashimotoT . Germinal matrix hemorrhage of venous origin in preterm neonates. Human Pathology1990;21(10):1059-62. [PMID: 2210729]">Nakamura 1990</a>; <a href="./references#CD013201-bbs2-0131" title="PapeKE , WigglesworthJS . Haemorrhage, Ischaemia and the Perinatal Brain. Philadelphia (PA): J.B. Lippincott, 1979.">Pape 1979</a>), thereby exposing this particular area to arterial ischaemia‐reperfusion insults and to venous congestion (<a href="./references#CD013201-bbs2-0131" title="PapeKE , WigglesworthJS . Haemorrhage, Ischaemia and the Perinatal Brain. Philadelphia (PA): J.B. Lippincott, 1979.">Pape 1979</a>; <a href="./references#CD013201-bbs2-0167" title="TakashimaS , TanakaK . Microangiography and vascular permeability of the subependymal matrix in the premature infant. Canadien des Sciences Neurologiques1978;5(1):45-50. [PMID: 647497]">Takashima 1978</a>). The immature deep galenic system is highly susceptible to venous congestion and stasis, thus playing a central role in the advancement of GMH‐IVH and its sequelae (<a href="./references#CD013201-bbs2-0131" title="PapeKE , WigglesworthJS . Haemorrhage, Ischaemia and the Perinatal Brain. Philadelphia (PA): J.B. Lippincott, 1979.">Pape 1979</a>; <a href="./references#CD013201-bbs2-0183" title="VolpeJV . Neurology of the Newborn. 5th edition. Philadelphia (PA): Saunders, 2008.">Volpe 2008</a>). </p> </section> </section> <section id="CD013201-sec-0013"> <h5 class="title">Encephalopathy of prematurity</h5> <p>The term 'EoP' was introduced by Volpe in 2005 to describe the injury to the white and grey matter in the preterm infant (<a href="./references#CD013201-bbs2-0182" title="VolpeJJ . Encephalopathy of prematurity includes neuronal abnormalities. Pediatrics2005;116(1):221-5. [DOI: 10.1542/peds.2005-0191] [PMID: 15995055]">Volpe 2005</a>). The injury to the neuronal/axonal unit, affecting the brain white matter, thalamus, basal ganglia, cerebral cortex, and cerebellum, leads to cognitive, behavioural, or socialisation deficits in 25% to 50%, and major motor deficits (e.g. cerebral palsy) in 5% to 10% of extremely preterm infants (<a href="./references#CD013201-bbs2-0110" title="MorsingE , LundgrenP , Hård A-L, RakowA , Hellström-WestasL , JacobsonL , et al. Neurodevelopmental disorders and somatic diagnoses in a national cohort of children born before 24 weeks of gestation. Acta Paediatrica2022;111(6):1167-75. [DOI: 10.1111/apa.16316] [PMID: 35318709]">Morsing 2022</a>; <a href="./references#CD013201-bbs2-0127" title="O'ReillyH , JohnsonS , NiY , WolkeD , MarlowN . Neuropsychological outcomes at 19 years of age following extremely preterm birth. Pediatrics2020;145(2):e20192087. [DOI: 10.1542/peds.2019-2087] [PMID: 31924688]">O'Reilly 2020</a>; <a href="./references#CD013201-bbs2-0185" title="VolpeJJ . Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances. Lancet Neurology2009;8(1):110-24. [DOI: 10.1016/S1474-4422(08)70294-1] [PMID: 19081519]">Volpe 2009b</a>). Due to the increased survival of extremely preterm infants (<a href="./references#CD013201-bbs2-0079" title="IshiiN , KonoY , YonemotoN , KusudaS , FujimuraM , Neonatal Research Network, Japan. Outcomes of infants born at 22 and 23 weeks' gestation. Pediatrics2013;132(1):62-71. [DOI: 10.1542/peds.2012-2857] [PMID: 23733804]">Ishii 2013</a>; <a href="./references#CD013201-bbs2-0125" title="NormanM , HallbergB , AbrahamssonT , BjorklundLJ , DomellofM , FarooqiM , et al. Association between year of birth and 1-year survival among extremely preterm infants in Sweden during 2004–2007 and 2014–2016. JAMA2019;321:1188-99. [DOI: 10.1001/jama.2019.2021] [PMID: 30912837]">Norman 2019</a>; <a href="./references#CD013201-bbs2-0195" title="YoungeN , GoldsteinRF , BannCM , HintzSR , PatelMR , SmithBP , et al, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Survival and neurodevelopmental outcomes among periviable infants. New England Journal Of Medicine2017;376:617-28. [DOI: 10.1056/NEJMoa1605566] [PMID: 28199816]">Younge 2017</a>), the issue of EoP becomes really substantial with a significant contribution to the burden of disability. Cognitive and behavioural abnormalities without any major motor impairment are dominant neurodevelopmental sequelae following preterm birth. Traditionally, neonatal brain injury was referred to as either cerebral lesion or tissue loss (<a href="./references#CD013201-bbs2-0186" title="VolpeJJ . The encephalopathy of prematurity-brain injury and impaired brain development inextricably intertwined. Seminars in Pediatric Neurology2009;16(4):167-78. [DOI: 10.1016/j.spen.2009.09.005] [PMID: 19945651]">Volpe 2009c</a>). However, since the 1990s, thanks to advancements in neonatal neurology, neuroradiology, and developmental neurobiology, the mapping out the pathophysiology of brain injury and the role of maturation‐dependent factors made it possible to identify specific brain regions and cell types that are vulnerable to injury (<a href="./references#CD013201-bbs2-0185" title="VolpeJJ . Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances. Lancet Neurology2009;8(1):110-24. [DOI: 10.1016/S1474-4422(08)70294-1] [PMID: 19081519]">Volpe 2009b</a>; <a href="./references#CD013201-bbs2-0186" title="VolpeJJ . The encephalopathy of prematurity-brain injury and impaired brain development inextricably intertwined. Seminars in Pediatric Neurology2009;16(4):167-78. [DOI: 10.1016/j.spen.2009.09.005] [PMID: 19945651]">Volpe 2009c</a>; <a href="./references#CD013201-bbs2-0184" title="VolpeJJ . Cerebellum of the premature infant: rapidly developing, vulnerable, clinically important. Journal of Child Neurology2009;24(9):1085-104. [DOI: 10.1177/0883073809338067] [PMID: 19745085]">Volpe 2009a</a>). Thus, EoP reflects in both primary brain injury and in mechanisms related to brain development. The most fragile perinatal period seems to be between gestational weeks 22 to 32, in which the final stages of neurogenesis, neuronal migration, differentiation, maturation, synaptogenesis, and initial cortical myelination take place (<a href="./references#CD013201-bbs2-0058" title="FleissB , GressensP , StolpH . Cortical gray matter injury in encephalopathy of prematurity: link to neurodevelopmental disorders. Frontiers in Neurology2020;11:575. [DOI: 10.3389/fneur.2020.00575] [PMID: 32765390]">Fleiss 2020</a>; <a href="./references#CD013201-bbs2-0186" title="VolpeJJ . The encephalopathy of prematurity-brain injury and impaired brain development inextricably intertwined. Seminars in Pediatric Neurology2009;16(4):167-78. [DOI: 10.1016/j.spen.2009.09.005] [PMID: 19945651]">Volpe 2009c</a>). These neurodevelopmental events are highly vulnerable to endogenous and exogenous insults, such as infection/inflammation (often the onset is antenatal), hyperoxia, hypoxia‐ischaemia, and excitotoxicity (<a href="./references#CD013201-bbs2-0185" title="VolpeJJ . Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances. Lancet Neurology2009;8(1):110-24. [DOI: 10.1016/S1474-4422(08)70294-1] [PMID: 19081519]">Volpe 2009b</a>). Currently, no treatment is available. </p> <p>Due to the lack of specific clinical signs in the neonatal period, the diagnosis of EoP relies on neuroimaging studies, such as cerebral ultrasound and magnetic resonance imaging (MRI), and neurophysiological studies, such as electroencephalogram. In older infants and children who developed EoP, the neurodevelopmental impairment may include co‐ordination problems, cognitive difficulties, visual impairment, and behavioural and socialisation problems. Neuroimaging may be helpful to predict neurodevelopmental disabilities to some extent; however, some problems will become more evident at school age. </p> <section id="CD013201-sec-0014"> <h6 class="title">Pathophysiology of encephalopathy of prematurity</h6> <p>The multifactorial pathophysiology of EoP includes systemic infection/inflammation, hypoxia‐hyperoxia‐ischaemia, and alteration in glucose metabolism (as hypo‐/hyperglycaemia), which results in toxicity to pre‐oligodendrocytes, neurons, and axons caused by free radicals, cytokines, and unbalance in excitatory/inhibitory neurotransmitters. It involves both cerebral white and grey matter. There is a spectrum of white matter injury (WMI) varying from diffuse non‐destructive injury to necrotic lesions known as PVL. While damage to white matter in PVL is characterised by the loss of axons, oligodendrocytes, glia, and interstitial neurons, leading to a myelination failure and retrograde degeneration of axons resulting in neuronal loss in the cerebral grey matter, the diffuse white matter injury (dWMI) is characterised by selective degeneration of preoligodendrocytes, leading to altered myelination due to differentiation failure of preoligodendrocytes to oligodendrocytes (<a href="./references#CD013201-bbs2-0021" title="BackSA , VolpeJJ . Volpe's Neurology of the Newborn. 6th edition. London (UK): Elsevier, 2018. [DOI: 10.1016/B978-0-323-42876-7.00015-6]">Back 2018</a>). Axons and interstitial neurons seem to be spared in dWMI, however, some experimental data suggest that larger calibre axons may be susceptible to hypoxic‐ischaemic injury during the later stages of myelination of white matter (<a href="./references#CD013201-bbs2-0016" title="AlixJJ , ZammitC , RiddleA , MeshulCK , BackSA , ValentinoM , et al. Central axons preparing to myelinate are highly sensitive to ischemic injury. Annals of neurology2012;72(6):936-51. [DOI: 10.1002/ana.23690] [PMID: 23280842]">Alix 2012</a>). Altogether, dWMI is characterised not only by hypomyelination but also by the aberrant organisation of myelin fibres. </p> <p>Along with WMI, there is increased recognition of grey matter involvement in the pathogenesis of EoP. Several MRI studies in preterm infants demonstrated the volumetric reduction of both cortical grey matter and deep grey matter with diffusivity alterations in thalamocortical networks (<a href="./references#CD013201-bbs2-0022" title="BallG , BoardmanJP , RueckertD , AljabarP , ArichiT , MerchantN , et al. The effect of preterm birth on thalamic and cortical development. Cerebral Cortex2012;22:1016-24. [DOI: 10.1093/cercor/bhr176] [PMID: 21772018]">Ball 2012</a>; <a href="./references#CD013201-bbs2-0023" title="BallG , PazderovaL , ChewA , TusorN , MerchantN , ArichiT , et al. Thalamocortical connectivity predicts cognition in children born preterm. Cerebral Cortex2015;25:4310-8. [DOI: 10.1093/cercor/bhu331] [PMID: 25596587]">Ball 2015</a>; <a href="./references#CD013201-bbs2-0031" title="BoardmanJP , CounsellSJ , RueckertD , KapellouO , BhatiaKK , AljabarP . Abnormal deep grey matter development following preterm birth detected using deformation-based morphometry. Neuroimage2006;2:708. [DOI: 10.1016/j.neuroimage.2006.03.029] [PMID: 16675269]">Boardman 2006</a>; <a href="./references#CD013201-bbs2-0101" title="MakropoulosA , AljabarP , WrightR , HuningB , MerchantN , ArichiT , et al. Regional growth and atlasing of the developing human brain. Neuroimage2016;125:456-78. [DOI: 10.1016/j.neuroimage.2015.10.047] [PMID: 26499811]">Makropoulos 2016</a>). These clinical data are supported by animal studies (<a href="./references#CD013201-bbs2-0046" title="CrumWR , SawiakSJ , ChegeW , CooperJD , WilliamsSC , VernonAC . Evolution of structural abnormalities in the rat brain following in utero exposure to maternal immune activation: a longitudinal in vivo MRI study. Brain Behaviour Immunity2017;63:50-9. [DOI: 10.1016/j.bbi.2016. 12.008] [PMID: 27940258]">Crum 2017</a>; <a href="./references#CD013201-bbs2-0049" title="DeanJM , vande LooijY , SizonenkoSV , LodygenskyGA , LazeyrasF , BolouriH , et al. Delayed cortical impairment following lipopolysaccharide exposure in preterm fetal sheep. Annals of Neurology2011;70:846-56. [DOI: 10.1002/ana.22480] [PMID: 22002627]">Dean 2011</a>; <a href="./references#CD013201-bbs2-0050" title="DeanJM , McClendonE , HansenK , Azimi-ZonoozA , ChenK , RiddleA , et al. Prenatal cerebral ischemia disrupts MRI-defined cortical microstructure through disturbances in neuronal arborization. Science Translational Medicine2013;5(168):168ra7. [DOI: 10.1126/scitranslmed.3004669] [PMID: 23325800]">Dean  2013</a>). Furthermore, preterm infants might show an alteration in cerebral cortex folding and gyrification, such as decreased cortical surface, and fewer and shallower sulci (<a href="./references#CD013201-bbs2-0055" title="EngelhardtE , InderTE , AlexopoulosD , DierkerDL , HillJ , vanEssenD , et al. Regional impairments of cortical folding in premature infants. Annals of Neurology2015;77(1):154-62. [DOI: 10.1002/ana.24313] [PMID: 25425403]">Engelhardt 2015</a>; <a href="./references#CD013201-bbs2-0086" title="KersbergenKJ , MakropoulosA , AljabarP , GroenendaalF , deVriesLS , CounsellSJ , et al. Longitudinal regional brain development and clinical risk factors in extremely preterm infants. Journal of Pediatrics2016;178:93-100e6. [DOI: 10.1016/j.jpeds.2016.08.024] [PMID: 27634629]">Kersbergen 2016</a>; <a href="./references#CD013201-bbs2-0099" title="LongKR , NewlandB , FlorioM , KalebicN , LangenB , KoltererA , et al. Extracellular matrix components HAPLN1, lumican, and collagen I cause hyaluronic acid-dependent folding of the developing human neocortex. Neuron2018;99:702-19e706. [DOI: 10.1016/j.neuron.2018.07.013] [PMID: 30078576]">Long 2018</a>; <a href="./references#CD013201-bbs2-0177" title="vanEssenDC , DonahueCJ , CoalsonTS , KennedyH , HayashiT , GlasserMF . Cerebral cortical folding, parcellation, and connectivity in humans, nonhuman primates, and mice. Proceedings of the National Academy of Sciences of the United States of America2019;116(52):26173-80. [DOI: 10.1073/pnas.1902299116] [PMID: 31871175]">van Essen 2019</a>; <a href="./references#CD013201-bbs2-0196" title="ZhangY , InderTE , NeilJJ , DierkerDL , AlexopoulosD , AndersonPJ , et al. Cortical structural abnormalities in very preterm children at 7 years of age. Neuroimage2015;109:469-79. [DOI: 10.1016/j.neuroimage.2015. 01.005] [PMID: 25614973]">Zhang 2015</a>). Reduced cortical folding appears to be associated with adverse neurodevelopment further in childhood (<a href="./references#CD013201-bbs2-0086" title="KersbergenKJ , MakropoulosA , AljabarP , GroenendaalF , deVriesLS , CounsellSJ , et al. Longitudinal regional brain development and clinical risk factors in extremely preterm infants. Journal of Pediatrics2016;178:93-100e6. [DOI: 10.1016/j.jpeds.2016.08.024] [PMID: 27634629]">Kersbergen 2016</a>). On a cellular level, a reduction in neurons and increased neuronal death in cerebral grey matter in newborns with PVL has been demonstrated (<a href="./references#CD013201-bbs2-0017" title="AndimanSE , HaynesRL , TrachtenbergFL , BilliardsSS , FolkerthRD , VolpeJJ , et al. The cerebral cortex overlying periventricular leukomalacia: analysis of pyramidal neurons. Brain Pathology2010;20(4):803-14. [DOI: 10.1111/j.1750-3639.2010.00380.x] [PMID: 20331617]">Andiman 2010</a>; <a href="./references#CD013201-bbs2-0069" title="HaynesRL , vanLeyenK . 12/15-lipoxygenase expression is increased in oligodendrocytes and microglia of periventricular leukomalacia. Developmental Neuroscience2013;35:140-54. [DOI: 10.1159/000350230] [PMID: 23838566]">Haynes 2013</a>; <a href="./references#CD013201-bbs2-0089" title="KinneyHC , HaynesRL , XuG , AndimanSE , FolkerthRD , SleeperLA , et al. Neuron deficit in the white matter and subplate in periventricular leukomalacia. Annals of neurology2012;71(3):397-406. [DOI: 10.1002/ana.22612] [PMID: 22451205]">Kinney 2012</a>; <a href="./references#CD013201-bbs2-0095" title="LigamP , HaynesRL , FolkerthRD , LiuL , YangM , VolpeJJ , et al. Thalamic damage in periventricular leukomalacia: novel pathologic observations relevant to cognitive deficits in survivors of prematurity. Pediatric Research2009;65:524-9. [DOI: 10.1203/PDR.0b013e3181998baf] [19127204]">Ligam 2009</a>), whereas in newborns with dWMI neuronal number seems to be not affected. However, subtle changes in interneurons are reported, such as the alteration in a population of different subtypes of interneurons (<a href="./references#CD013201-bbs2-0092" title="LacailleH , VacherCM , BakalarD , O'ReillyJJ , SalzbankJ , PennAA . Impaired interneuron development in a novel model of neonatal brain injury. eNeuro2019;6(1):ENEURO.0300-18.2019. [DOI: 10.1523/ENEURO.0300-18.2019] [PMID: 30809588]">Lacaille 2019</a>; <a href="./references#CD013201-bbs2-0130" title="PandaS , DohareP , JainS , ParikhN , SinglaP , MehdizadehR , et al. Estrogen treatment reverses prematurity-induced disruption in cortical interneuron population. Journal of Neuroscience2018;38(34):7378-91. [DOI: 10.1523/JNEUROSCI.0478-18.2018] [PMID: 30037831]">Panda 2018</a>; <a href="./references#CD013201-bbs2-0165" title="StolpHB , FleissB , AraiY , SupramaniamV , VontellR , BirtlesS , et al. Interneuron development is disrupted in preterm brains with diffuse white matter injury: observations in mouse and human. Frontiers in Physiology2019;10:955. [DOI: 10.3389/fphys.2019.00955]">Stolp 2019</a>). These pathological findings reported in preterm infants postmortem are confirmed by experimental data in animal models of EoP (<a href="./references#CD013201-bbs2-0018" title="ArdalanM , SvedinP , BaburamaniAA , SupramaniamVG , EkJ , HagbergH , et al. Dysmaturation of somatostatin interneurons following umbilical cord occlusion in preterm fetal sheep. Frontiers in Physiology2019;10:563. [DOI: 10.3389/fphys.2019.00563] [PMID: 31178744]">Ardalan 2019</a>; <a href="./references#CD013201-bbs2-0038" title="CanettaS , BolkanS , Padilla-CoreanoN , SongLJ , SahnR , HarrisonNL , et al. Maternal immune activation leads to selective functional deficits in offspring parvalbumin interneurons. Molecular Psychiatry2016;21:956-68. [DOI: 10.1038/mp.2015.222] [PMID: 26830140]">Canetta 2016</a>; <a href="./references#CD013201-bbs2-0092" title="LacailleH , VacherCM , BakalarD , O'ReillyJJ , SalzbankJ , PennAA . Impaired interneuron development in a novel model of neonatal brain injury. eNeuro2019;6(1):ENEURO.0300-18.2019. [DOI: 10.1523/ENEURO.0300-18.2019] [PMID: 30809588]">Lacaille 2019</a>; <a href="./references#CD013201-bbs2-0130" title="PandaS , DohareP , JainS , ParikhN , SinglaP , MehdizadehR , et al. Estrogen treatment reverses prematurity-induced disruption in cortical interneuron population. Journal of Neuroscience2018;38(34):7378-91. [DOI: 10.1523/JNEUROSCI.0478-18.2018] [PMID: 30037831]">Panda 2018</a>; <a href="./references#CD013201-bbs2-0165" title="StolpHB , FleissB , AraiY , SupramaniamV , VontellR , BirtlesS , et al. Interneuron development is disrupted in preterm brains with diffuse white matter injury: observations in mouse and human. Frontiers in Physiology2019;10:955. [DOI: 10.3389/fphys.2019.00955]">Stolp 2019</a>; <a href="./references#CD013201-bbs2-0175" title="VaesJE , KosmeijerCM , KaalM , vanVlietR , BrandtMJ , BendersMJ , et al. Regenerative therapies to restore interneuron disturbances in experimental models of encephalopathy of prematurity. International Journal of Molecular Sciences2020;22(1):211. [DOI: 10.3390/ijms22010211] [PMID: 33379239]">Vaes 2020</a>). Furthermore, the complexity of dendritic arborisation and synapse formation – which are essential for proper connectivity in the brain – seems to be reduced for certain populations of interneurons (<a href="./references#CD013201-bbs2-0049" title="DeanJM , vande LooijY , SizonenkoSV , LodygenskyGA , LazeyrasF , BolouriH , et al. Delayed cortical impairment following lipopolysaccharide exposure in preterm fetal sheep. Annals of Neurology2011;70:846-56. [DOI: 10.1002/ana.22480] [PMID: 22002627]">Dean 2011</a>; <a href="./references#CD013201-bbs2-0165" title="StolpHB , FleissB , AraiY , SupramaniamV , VontellR , BirtlesS , et al. Interneuron development is disrupted in preterm brains with diffuse white matter injury: observations in mouse and human. Frontiers in Physiology2019;10:955. [DOI: 10.3389/fphys.2019.00955]">Stolp 2019</a>). </p> </section> </section> </section> </section> <section id="CD013201-sec-0015"> <h3 class="title" id="CD013201-sec-0015">Description of the intervention</h3> <p>Advances in stem cell research have highlighted the therapeutic potential of regenerative cells. At the forefront of these cell‐based therapies is the mesenchymal stem/stromal cell (MSC). MSCs are the most commonly used regenerative cells in clinical trials due to their relatively safe profile, ease of isolation and propagation, and pleiotropic effects in preventing/restoring organ damage (<a href="./references#CD013201-bbs2-0172" title="TrounsonA , McdonaldC . Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell2015;17(1):11-22. [DOI: 10.1016/j.stem.2015.06.007] [PMID: 26140604]">Trounson 2015</a>). The minimum criteria for defining MSCs include adherence to plastic in standard culture conditions; expression and lack of specific surface markers; and multipotent differentiation potential along the osteogenic, chondrogenic, and adipogenic lineages (<a href="./references#CD013201-bbs2-0052" title="DominiciM , Le BlancK , MuellerI , Slaper-CortenbachI , MariniF , KrauseD , et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy2006;8(4):315-7. [DOI: 10.1080/14653240600855905] [PMID: 16923606]">Dominici 2006</a>). Although MSCs are ubiquitously used in regenerative studies, other cell‐based therapies are beginning to receive attention. For instance, mononuclear cells (MNC), oligodendrocyte progenitor cells (OPCs), neural stem cells (NSC), haematopoietic stem cells, and inducible pluripotent stem cells (iPSC) have demonstrated efficacy in animal models of brain injury (see <a href="#CD013201-tbl-0001">Table 1</a>; <a href="./references#CD013201-bbs2-0143" title="PhillipsLK , GouldEA , BabuH , KramsSM , PalmerTD , MartinezOM . Natural killer cell-activating receptor NKG2D mediates innate immune targeting of allogeneic neural progenitor cell grafts. Stem Cells (Dayton, Ohio)2013;31(9):1829-39. [DOI: 10.1002/stem.1422] [PMID: 23733329]">Phillips 2013</a>; <a href="./references#CD013201-bbs2-0145" title="Pimentel-CoelhoPM , Rosado-de-CastroPH , da FonsecaLM , Mendez-OteroR . Umbilical cord blood mononuclear cell transplantation for neonatal hypoxic-ischemic encephalopathy. Pediatric Research2012;71(4 Pt 2):464-73. [DOI: 10.1038/pr.2011.59] [PMID: 22430382]">Pimentel‐Coelho 2012</a>). Furthermore, one ongoing clinical trial using autologous human umbilical cord blood for neonatal asphyxia contains a heterogeneous mixture of these cells (MSCs, haematopoietic stem cells, and other MNCs) (<a href="./references#CD013201-bbs2-0117" title="NCT02612155. A multi-site study of autologous cord blood cells for hypoxic-ischemic encephalopathy (HIE). clinicaltrials.gov/ct2/show/NCT0261215 (first received 23 November 2015).">NCT02612155</a>). Although iPSCs are typically obtained from skin cells, they can also be retrieved from blood or MSCs to become a specialised cell, such as a NSC or an oligodendrocyte (<a href="./references#CD013201-bbs2-0037" title="CaiJ , LiW , SuH , QinD , YangJ , ZhuF , et al. Generation of human induced pluripotent stem cells from umbilical cord matrix and amniotic membrane mesenchymal cells. Journal of Biological Chemistry2010;285(15):11227-34. [DOI: 10.1074/jbc.M109.086389] [PMID: 20139068]">Cai 2010</a>). </p> <div class="table" id="CD013201-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Types of regenerative cells</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Cell type</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Source</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rationale</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mechanism of action</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Preclinical/clinical results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>References</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Human umbilical cord tissue/blood; rodent/human bone marrow</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safe and feasible in phase 1 RCT for bronchopulmonary dysplasia</p> <p> <ul id="CD013201-list-0001"> <li> <p>Low immunogenicity (low MHC II), easily obtainable, rapid expansion</p> </li> <li> <p>Autologous/allogeneic administration</p> </li> <li> <p>Paracrine release of trophic factors</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0002"> <li> <p>Paracrine release of IGF‐1, EGF, VEGF, BDNF</p> </li> <li> <p>Immunomodulatory: regulate T‐cell, B‐cell function, and production of inflammatory cytokines </p> </li> <li> <p>Mitochondrial transfer</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0003"> <li> <p>Nerve fibre remyelination and axonal regeneration; improve behavioural/motor tests</p> </li> <li> <p>Enhance neural cell proliferation, survival, function</p> </li> <li> <p>Decrease infarct size</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013201-bbs2-0015" title="AhnSY , ChangYS , ParkWS . Stem cells for neonatal brain disorders. Neonatology2016;109(4):377-83. [PMID: 27251746]">Ahn 2016</a>; <a href="./references#CD013201-bbs2-0034" title="BoshuizenMC , SteinbergGK . Stem cell-based immunomodulation after stroke: effects on brain repair processes. Stroke2018;49(6):1563-70. [PMID: 29724892]">Boshuizen 2018</a>; <a href="./references#CD013201-bbs2-0042" title="ChoppM , LiY . Treatment of neural injury with marrow stromal cells. Lancet Neurology2002;1(2):92-100. [PMID: 12849513]">Chopp 2002</a>; <a href="./references#CD013201-bbs2-0075" title="HsuYC , WuYT , YuTH , WeiYH . Mitochondria in mesenchymal stem cell biology and cell therapy: from cellular differentiation to mitochondrial transfer. Seminars in Cell &amp; Developmental Biology2016;52:119-31. [DOI: 10.1016/j.semcdb.2016.02.011] [PMID: 26868759]">Hsu 2016</a>; <a href="./references#CD013201-bbs2-0080" title="IslamMN , DasSR , EminMT , WeiM , SunL , WestphalenK , et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nature Medicine2012;18(5):759-65. [DOI: 10.1038/nm.2736] [PMID: 22504485]">Islam 2012</a>; <a href="./references#CD013201-bbs2-0098" title="LiuAM , LuG , TsangKS , LiG , WuY , HuangZS , et al. Umbilical cord-derived mesenchymal stem cells with forced expression of hepatocyte growth factor enhance remyelination and functional recovery in a rat intracerebral hemorrhage model. Neurosurgery2010;67(2):357-65; discussion 365-6. [DOI: 10.1227/01.NEU.0000371983.06278.B3] [PMID: 20644422]">Liu 2010</a>; <a href="./references#CD013201-bbs2-0113" title="MurphyMB , MoncivaisK , CaplanAI . Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Experimental &amp; Molecular Medicine2013;45(11):e54. [DOI: 10.1038/emm.2013.94] [PMID: 24232253]">Murphy 2013</a>; <a href="./references#CD013201-bbs2-0133" title="ParkWS , SungSI , AhnSY , SungDK , ImGH , YooHS , et al. Optimal timing of mesenchymal stem cell therapy for neonatal intraventricular hemorrhage. Cell Transplantation2016;25(6):1131-44. [DOI: 10.3727/096368915X689640] [PMID: 26440762]">Park 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MNC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Human umbilical cord blood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0004"> <li> <p>Readily collected and large supply in cord blood with high plasticity</p> </li> <li> <p>Safe and feasible in phase 1 RCT for hypoxic‐ischaemic encephalopathy</p> </li> <li> <p>Low immunogenicity (minimal HLA matching)</p> </li> <li> <p>Paracrine release of trophic factors</p> </li> <li> <p>Autologous/allogeneic administration</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0005"> <li> <p>Increase expression of BDNF, NGF, VEGF, GDNF</p> </li> <li> <p>Activate prosurvival Akt pathway</p> </li> <li> <p>Decrease TNF‐α and increase IL‐10 gene expression</p> </li> <li> <p>Reduce CD4+ T‐cell infiltration</p> </li> <li> <p>Regulate hedgehog signalling</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0006"> <li> <p>Decrease neuronal apoptosis, astrogliosis, inflammation</p> </li> <li> <p>Improve oligodendrocyte survival; induce axonal growth</p> </li> <li> <p>Improve neurobehavioural outcomes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013201-bbs2-0019" title="AridasJD , McDonaldCA , PatonMC , YawnoT , SutherlandAE , NitsosI , et al. Cord blood mononuclear cells prevent neuronal apoptosis in response to perinatal asphyxia in the newborn lamb. Journal of Physiology2016;594(5):1421-35. [DOI: 10.1113/JP271104] [PMID: 26527561]">Aridas 2016</a>; <a href="./references#CD013201-bbs2-0045" title="CottenCM , MurthaAP , GoldbergRN , GrotegutCA , SmithPB , GoldsteinRF , et al. Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy. Journal of Pediatrics2014;164(5):973-9.e1. [DOI: 10.1016/j.jpeds.2013.11.036] [PMID: 24388332]">Cotten 2014</a>; <a href="./references#CD013201-bbs2-0057" title="FanCG , ZhangQJ , TangFW , HanZB , WangGS , HanZC . Human umbilical cord blood cells express neurotrophic factors. Neuroscience Letters2005;380(3):322-5. [DOI: 10.1016/j.neulet.2005.01.070] [PMID: 15862910]">Fan 2005</a>; <a href="./references#CD013201-bbs2-0104" title="McDonaldCA , PennyTR , PatonMC , SutherlandAE , NekkantiL , YawnoT , et al. Effects of umbilical cord blood cells, and subtypes, to reduce neuroinflammation following perinatal hypoxic-ischemic brain injury. Journal of Neuroinflammation2018;15(1):47. [PMID: 29454374]">McDonald 2018</a>; <a href="./references#CD013201-bbs2-0145" title="Pimentel-CoelhoPM , Rosado-de-CastroPH , da FonsecaLM , Mendez-OteroR . Umbilical cord blood mononuclear cell transplantation for neonatal hypoxic-ischemic encephalopathy. Pediatric Research2012;71(4 Pt 2):464-73. [DOI: 10.1038/pr.2011.59] [PMID: 22430382]">Pimentel‐Coelho 2012</a>; <a href="./references#CD013201-bbs2-0153" title="RoweDD , LeonardoCC , HallAA , ShahaduzzamanMD , CollierLA , WillingAE , et al. Cord blood administration induces oligodendrocyte survival through alterations in gene expression. Brain Research2010;1366:172-88. [DOI: 10.1016/j.brainres.2010.09.078] [PMID: 20883670]">Rowe 2010</a>; <a href="./references#CD013201-bbs2-0189" title="WangXL , ZhaoYS , HuMY , SunYQ , ChenYX , BiXH . Umbilical cord blood cells regulate endogenous neural stem cell proliferation via hedgehog signaling in hypoxic ischemic neonatal rats. Brain Research2013;1518:26-35. [DOI: 10.1016/j.brainres.2013.04.038] [PMID: 23632377]">Wang 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OPC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rodent/human ESC; human NSC derivation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0007"> <li> <p>Differentiate into oligodendrocytes (cells highly susceptible to hypoxic‐ischaemic injury) </p> </li> <li> <p>Remyelinate injured axons</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0008"> <li> <p>Diffuse biodistribution along white matter tracts and differentiate into myelin sheath‐producing oligodendrocytes </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0009"> <li> <p>Promote myelin sheath formation and NSC proliferation, inhibit apoptosis</p> </li> <li> <p>Motor recovery following CNS injury</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013201-bbs2-0041" title="ChenLX , MaSM , ZhangP , FanZC , XiongM , ChengGQ , et al. Neuroprotective effects of oligodendrocyte progenitor cell transplantation in premature rat brain following hypoxic-ischemic injury. PLOS One2015;10(3):e0115997. [PMID: 25790286]">Chen 2015</a>; <a href="./references#CD013201-bbs2-0064" title="GopagondanahalliKR , LiJ , FaheyMC , HuntRW , JenkinG , MillerSL , et al. Preterm hypoxic-ischemic encephalopathy. Frontiers in Pediatrics2016;4:114. [DOI: 10.3389/fped.2016.00114] [PMID: 27812521]">Gopagondanahalli 2016</a>; <a href="./references#CD013201-bbs2-0088" title="KimTK , ParkD , BanYH , ChaY , AnES , ChoiJ , et al. Improvement by human oligodendrocyte progenitor cells of neurobehavioral disorders in an experimental model of neonatal periventricular leukomalacia. Cell Transplantation2018;27(7):1168-77. [DOI: 10.1177/0963689718781330] [PMID: 29978719]">Kim 2018</a>; <a href="./references#CD013201-bbs2-0102" title="ManleyNC , PriestCA , DenhamJ , Wirth ED 3rd, LebkowskiJS . Human embryonic stem cell-derived oligodendrocyte progenitor cells: preclinical efficacy and safety in cervical spinal cord injury. Stem Cells Translational Medicine2017;6(10):1917-29. [DOI: 10.1002/sctm.17-0065] [PMID: 28834391]">Manley 2017</a>; <a href="./references#CD013201-bbs2-0123" title="NiimiY , LevisonSW . Pediatric brain repair from endogenous neural stem cells of the subventricular zone. Pediatric Research2018;83(1-2):385-96. [DOI: 10.1038/pr.2017.261] [PMID: 29028220]">Niimi 2018</a>; <a href="./references#CD013201-bbs2-0193" title="XuL , RyuJ , HielH , MenonA , AggarwalA , RhaE , et al. Transplantation of human oligodendrocyte progenitor cells in an animal model of diffuse traumatic axonal injury: survival and differentiation. Stem Cell Research &amp; Therapy2015;6:93. [DOI: 10.1186/s13287-015-0087-0] [PMID: 25971252]">Xu 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Human foetal striatum; human ESC; human iPSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0010"> <li> <p>Differentiate into cells necessary for brain repair, including neurons, astrocytes, and oligodendrocytes </p> </li> <li> <p>Paracrine release of trophic factors</p> </li> <li> <p>Low immunogenicity and tumorigenicity</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0011"> <li> <p>Immunomodulation</p> </li> <li> <p>Paracrine secretion of BDNF, VEGF, and EGF</p> </li> <li> <p>Attenuate NF‐κB signalling</p> </li> <li> <p>Upregulate glutamate transport</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD013201-list-0012"> <li> <p>Stimulate survival and migration of endogenous NSCs and neurons</p> </li> <li> <p>Reduce inflammation and reactive oxygen species production</p> </li> <li> <p>Improve axonal growth, motor function; decrease infarct size</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013201-bbs2-0047" title="DaadiMM , KlausnerJQ , BajarB , GoshenI , Lee-MesserC , LeeSY , et al. Optogenetic stimulation of neural grafts enhances neurotransmission and downregulates the inflammatory response in experimental stroke model. Cell Transplantation2016;25(7):1371-80. [DOI: 10.3727/096368915X688533] [PMID: 26132738]">Daadi 2016</a>; <a href="./references#CD013201-bbs2-0076" title="HuangL , ZhangL . Neural stem cell therapies and hypoxic-ischemic brain injury. Progress in Neurobiology2018;173:1-17. [DOI: 10.1016/j.pneurobio.2018.05.004] [PMID: 29758244]">Huang 2018</a>; <a href="./references#CD013201-bbs2-0084" title="JiG , LiuM , ZhaoXF , LiuXY , GuoQL , GuanZF , et al. NF-kappaB signaling is involved in the effects of intranasally engrafted human neural stem cells on neurofunctional improvements in neonatal rat hypoxic-ischemic encephalopathy. CNS Neuroscience &amp; Therapeutics2015;21(12):926-35. [DOI: 10.1111/cns.12441] [PMID: 26255634]">Ji 2015</a>; <a href="./references#CD013201-bbs2-0106" title="MineY , TatarishviliJ , OkiK , MonniE , KokaiaZ , LindvallO . Grafted human neural stem cells enhance several steps of endogenous neurogenesis and improve behavioral recovery after middle cerebral artery occlusion in rats. Neurobiology of Disease2013;52:191-203. [DOI: 10.1016/j.nbd.2012.12.006] [PMID: 23276704]">Mine 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Umbilical cord blood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0013"> <li> <p>Paracrine release of neurotrophic factors</p> </li> <li> <p>Multipotent capacity and ability to transdifferentiate into neuronal cells</p> </li> <li> <p>Autologous/allogeneic administration</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0014"> <li> <p>Reduce microglial cells and T lymphocytes</p> </li> <li> <p>Secrete VEGF, HGF, IGF‐1</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD013201-list-0015"> <li> <p>Decrease infarct size and maintain cerebral blood flow</p> </li> <li> <p>Enhance axonal growth</p> </li> <li> <p>Ameliorate neuronal apoptosis and postischaemic inflammation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013201-bbs2-0159" title="SchwartingS , LitwakS , HaoW , BahrM , WeiseJ , NeumannH . Hematopoietic stem cells reduce postischemic inflammation and ameliorate ischemic brain injury. Stroke2008;39(10):2867-75. [DOI: 10.1161/STROKEAHA.108.513978] [PMID: 18658037]">Schwarting 2008</a>; <a href="./references#CD013201-bbs2-0174" title="TsujiM , TaguchiA , OhshimaM , KasaharaY , SatoY , TsudaH , et al. Effects of intravenous administration of umbilical cord blood CD34(+) cells in a mouse model of neonatal stroke. Neuroscience2014;263:148-58. [PMID: 24444827]">Tsuji 2014</a>; <a href="./references#CD013201-bbs2-0181" title="VerinaT , FatemiA , JohnstonMV , ComiAM . Pluripotent possibilities: human umbilical cord blood cell treatment after neonatal brain injury. Pediatric Neurology2013;48(5):346-54. [DOI: 10.1016/j.pediatrneurol.2012.10.010] [PMID: 23583051]">Verina 2013</a> </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>iPSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skin fibroblasts, umbilical cord tissue, amniotic tissue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0016"> <li> <p>Autologous administration</p> </li> <li> <p>Differentiation into multiple neural lineage cells</p> </li> <li> <p>Low immunogenicity</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD013201-list-0017"> <li> <p>Differentiate into functional neural cells (electrophysiological properties)</p> </li> <li> <p>Decrease infiltration of MPO+ neutrophils and CD11b+ microglia</p> </li> <li> <p>VEGF expression and organelle transfer</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0018"> <li> <p>Improve survival and sensorimotor function</p> </li> <li> <p>Establish axonal connections</p> </li> <li> <p>Inhibit inflammation, neural apoptosis, and glial scar formation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013201-bbs2-0037" title="CaiJ , LiW , SuH , QinD , YangJ , ZhuF , et al. Generation of human induced pluripotent stem cells from umbilical cord matrix and amniotic membrane mesenchymal cells. Journal of Biological Chemistry2010;285(15):11227-34. [DOI: 10.1074/jbc.M109.086389] [PMID: 20139068]">Cai 2010</a>; <a href="./references#CD013201-bbs2-0075" title="HsuYC , WuYT , YuTH , WeiYH . Mitochondria in mesenchymal stem cell biology and cell therapy: from cellular differentiation to mitochondrial transfer. Seminars in Cell &amp; Developmental Biology2016;52:119-31. [DOI: 10.1016/j.semcdb.2016.02.011] [PMID: 26868759]">Hsu 2016</a>; <a href="./references#CD013201-bbs2-0128" title="OkiK , TatarishviliJ , WoodJ , KochP , WattananitS , MineY , et al. Human-induced pluripotent stem cells form functional neurons and improve recovery after grafting in stroke-damaged brain. Stem Cells2012;30(6):1120-33. [DOI: 10.1002/stem.1104] [PMID: 22495829]">Oki 2012</a>; <a href="./references#CD013201-bbs2-0146" title="PluchinoS , Peruzzotti-JamettiL . Rewiring the ischaemic brain with human-induced pluripotent stem cell-derived cortical neurons. Brain2013;136(Pt 12):3525-7. [PMID: 24335051]">Pluchino 2013</a>; <a href="./references#CD013201-bbs2-0148" title="QinJ , MaX , QiH , SongB , WangY , WenX , et al. Transplantation of induced pluripotent stem cells alleviates cerebral inflammation and neural damage in hemorrhagic stroke. PLOS One2015;10(6):e0129881. [PMID: 26086994]">Qin 2015</a>; <a href="./references#CD013201-bbs2-0171" title="TorneroD , WattananitS , Gronning MadsenM , KochP , WoodJ , TatarishviliJ , et al. Human induced pluripotent stem cell-derived cortical neurons integrate in stroke-injured cortex and improve functional recovery. Brain2013;136(Pt 12):3561-77. [DOI: 10.1093/brain/awt278] [PMID: 24148272]">Tornero 2013</a> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BDNF: brain‐derived neurotrophic factor; CNS: central nervous system; EGF: epidermal growth factor; ESC: embryonic stem cell; GDNF: glial cell‐line‐derived neurotrophic factor; HGF: hepatocyte growth factor; HLA: human leukocyte antigen; HSC: haematopoietic stem cell; IGF‐1: insulin‐like growth factor‐1; IL: interleukin; iPSC: inducible pluripotent stem cell; MHC: major histocompatibility complex; MNC: mononuclear cell; MSC: mesenchymal stem cell; NF‐κB: nuclear factor kappa beta; NGF: nerve growth factor; NSC: neural stem cell; OPC: oligodendrocyte progenitor cell; RCT: randomised controlled trial; TNF: tumour necrosis factor; VEGF: vascular endothelial growth factor. </p> </div> </div> <p>Aside from cell type, tissue source and laboratory processing may affect the efficacy of the regenerative cell. The perinatal period offers an opportune time to collect umbilical cord tissue/blood, amniotic fluid, or placental tissue (<a href="./references#CD013201-bbs2-0062" title="GarciaO , WarburtonD . Amniotic fluid stem cell therapy for lung disease. In: AtalaA , MurphyS , editors(s). Perinatal Stem Cells. New York (NY): Springer New York, 2014:59-66. [DOI: 10.1007/978-1-4939-1118-9_6]">Garcia 2014</a>; <a href="./references#CD013201-bbs2-0136" title="ParoliniO , DeD , RodriguesM , CarusoM . Placental stem/progenitor cells: isolation and characterization. In: Perinatal Stem Cells. New York (NY): Springer, 2014:141-57.">Parolini 2014</a>; <a href="./references#CD013201-bbs2-0155" title="SanbergPR , EveDJ , BorlonganCV . Umbilical cord blood cells in the repair of central nervous system diseases. In: AtalaA , MurphyS , editors(s). Perinatal Stem Cells. New York (NY): Springer, 2014:269-87. [DOI: 10.1007/978-1-4939-1118-9_25]">Sanberg 2014</a>; <a href="./references#CD013201-bbs2-0166" title="TaghizadehRR , HolzerPW , MarinoT , CetruloKJ , CetruloCL , CetruloCL . Towards clinical applications of umbilical cord derived mesenchymal stem cells. In: AtalaA , MurphyS , editors(s). Perinatal Stem Cells. New York (NY): Springer, 2014:347-59. [DOI: 10.1007/978-1-4939-1118-9_31]">Taghizadeh 2014</a>). These sources are considered medical waste and therefore are easily available in a non‐invasive manner and offer reduced immunogenicity and higher differential potential compared to other sites (<a href="./references#CD013201-bbs2-0026" title="BatsaliAK , KastrinakiMC , PapadakiHA , PontikoglouC . Mesenchymal stem cells derived from Wharton's Jelly of the umbilical cord: biological properties and emerging clinical applications. Current Stem Cell Research &amp; Therapy2013;8(2):144-55. [PMID: 23279098]">Batsali 2013</a>; <a href="./references#CD013201-bbs2-0135" title="ParoliniO , AlvianoF , BagnaraGP , BilicG , BühringHJ , EvangelistaM , et al. Concise review: isolation and characterization of cells from human term placenta: outcome of the first international workshop on placenta derived stem cells. Stem Cells2008;26(2):300-11. [DOI: 10.1634/stemcells.2007-0594] [PMID: 17975221]">Parolini 2008</a>). The therapeutic potential of regenerative cells may also be influenced by passage number. A passage consists of removing cells from a culture flask and plating them into more culture flasks. Fewer passages are preferred, as multiple passages may impair cell function (<a href="./references#CD013201-bbs2-0030" title="BellayrIH , CatalanoJG , LababidiS , YangAX , Lo SurdoJL , BauerSR , et al. Gene markers of cellular aging in human multipotent stromal cells in culture. Stem Cell Research &amp; Therapy2014;5(2):59. [DOI: 10.1186/scrt448] [PMID: 24780490]">Bellayr 2014</a>; <a href="./references#CD013201-bbs2-0187" title="WagnerW , HornP , CastoldiM , DiehlmannA , BorkS , SaffrichR , et al. Replicative senescence of mesenchymal stem cells: a continuous and organized process. PLOS One2008;3(5):e2213. [DOI: 10.1371/journal.pone.0002213] [PMID: 18493317]">Wagner 2008</a>). It is interesting to note that cord blood from preterm infants contains a greater quantity of immature haematopoietic progenitor cells and MSCs that have higher proliferative capacity compared with term infants (<a href="./references#CD013201-bbs2-0147" title="PodestaM , BruschettiniM , CossuC , SabatiniF , DagninoM , RomantsikO , et al. Preterm cord blood contains a higher proportion of immature hematopoietic progenitors compared to term samples. PLOS One2015;10(9):e0138680. [DOI: 10.1371/journal.pone.0138680] [PMID: 26417990]">Podesta 2015</a>). </p> <p>Although regenerative cells are characterised by low immunogenicity (<a href="./references#CD013201-bbs2-0063" title="GeblerA , ZabelO , SeligerB . The immunomodulatory capacity of mesenchymal stem cells. Trends in Molecular Medicine2012;18(2):128-34. [DOI: 10.1016/j.molmed.2011.10.004] [PMID: 22118960]">Gebler 2012</a>), autologous transplantation is likely to be associated with lower risk for infection and immune rejection. However, allogeneic transplantation may offer significant practical advantages. </p> </section> <section id="CD013201-sec-0016"> <h3 class="title" id="CD013201-sec-0016">How the intervention might work</h3> <p>EoP may result in long‐term neurocognitive dysfunction, and behavioural and socialisation problems (<a href="./references#CD013201-bbs2-0185" title="VolpeJJ . Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances. Lancet Neurology2009;8(1):110-24. [DOI: 10.1016/S1474-4422(08)70294-1] [PMID: 19081519]">Volpe 2009b</a>; <a href="./references#CD013201-bbs2-0186" title="VolpeJJ . The encephalopathy of prematurity-brain injury and impaired brain development inextricably intertwined. Seminars in Pediatric Neurology2009;16(4):167-78. [DOI: 10.1016/j.spen.2009.09.005] [PMID: 19945651]">Volpe 2009c</a>). Despite the burden of disabilities caused by EoP no treatment is available. One of the hallmarks of EoP is hypomyelination and arrest of oligodendrocyte maturation. In several rodent models of EoP mimicking dWMI, MSCs (administered either intranasally or intraperitoneally) migrate into the damaged regions of the brain, restore oligodendrocyte maturation and improve myelination, attenuate neuroinflammation, resulting in the better functional outcome on neurobehavioral tests (<a href="./references#CD013201-bbs2-0111" title="MuellerM , OppligerB , Joerger-MesserliM , ReinhartU , BarneaE , PaidasM , et al. Wharton's jelly mesenchymal stem cells protect the immature brain in rats and modulate cell fate. Stem Cells and Development2017;26(4):239-48. [PMID: 27842457]">Mueller 2017</a>; <a href="./references#CD013201-bbs2-0129" title="OppligerB , Joerger-MesseliM , MuellerM , ReinhartU , SchneiderP , SurbekDV , et al. Intranasal delivery of umbilical cord-derived mesenchymal stem cells preserves myelination in perinatal brain damage. Stem Cells and Development2016;25(16):1234-42. [PMID: 27392671]">Oppliger 2016</a>; <a href="./references#CD013201-bbs2-0176" title="VaesJE , vanKammenCM , TrayfordC , van derToornA , RuhwedelT , BendersMJ , et al. Intranasal mesenchymal stem cell therapy to boost myelination after encephalopathy of prematurity. Glia2021;69(3):655-80. [DOI: 10.1002/glia.23919] [PMID: 33045105]">Vaes 2021</a>). Furthermore, in vitro studies demonstrated that MSCs express several growth factors, such as insulin‐like growth factor‐1 (IGF‐1), epidermal growth factor (EGF), leukaemia inhibitory factor (LIF), interleukin (IL)‐11 following ex vivo exposure to dWMI (<a href="./references#CD013201-bbs2-0176" title="VaesJE , vanKammenCM , TrayfordC , van derToornA , RuhwedelT , BendersMJ , et al. Intranasal mesenchymal stem cell therapy to boost myelination after encephalopathy of prematurity. Glia2021;69(3):655-80. [DOI: 10.1002/glia.23919] [PMID: 33045105]">Vaes 2021</a>). These factors are important for oligodendrocyte's maturational process. Additionally, in the sheep foetal model of dWMI, induced by either transient umbilical cord occlusion or intra‐uterine lipopolysaccharide (LPS) infusion, it has been shown that intravenous infusion of MSCs resulted in a reduction of oligodendrocytes loss, reduced demyelination, and microgliosis (<a href="./references#CD013201-bbs2-0083" title="JellemaRK , WolfsTG , Lima PassosV , ZwanenburgA , OpheldersDR , KuypersE , et al. Mesenchymal stem cells induce T-cell tolerance and protect the preterm brain after global hypoxia-ischemia. PLOS One2013;8(8):e73031. [DOI: 10.1371/journal.pone.0073031] [PMID: 23991170]">Jellema 2013</a>; <a href="./references#CD013201-bbs2-0094" title="LiJ , YawnoT , SutherlandA , LooseJ , NitsosI , BischofR , et al. Preterm white matter brain injury is prevented by early administration of umbilical cord blood cells. Experimental Neurology2016;283(Pt A):179-87. [DOI: 10.1016/j.expneurol.2016.06.017] [PMID: 27317990]">Li 2016</a>; <a href="./references#CD013201-bbs2-0137" title="PatonMC , AllisonBJ , LiJ , FaheyMC , SutherlandAE , NitsosI , et al. Human umbilical cord blood therapy protects cerebral white matter from systemic LPS exposure in preterm fetal sheep. Developmental Neuroscience2018;40(3):258-70. [DOI: 10.1159/000490943] [PMID: 30179864]">Paton 2018</a>), and diminished neuroinflammatory response (<a href="./references#CD013201-bbs2-0094" title="LiJ , YawnoT , SutherlandA , LooseJ , NitsosI , BischofR , et al. Preterm white matter brain injury is prevented by early administration of umbilical cord blood cells. Experimental Neurology2016;283(Pt A):179-87. [DOI: 10.1016/j.expneurol.2016.06.017] [PMID: 27317990]">Li 2016</a>; <a href="./references#CD013201-bbs2-0137" title="PatonMC , AllisonBJ , LiJ , FaheyMC , SutherlandAE , NitsosI , et al. Human umbilical cord blood therapy protects cerebral white matter from systemic LPS exposure in preterm fetal sheep. Developmental Neuroscience2018;40(3):258-70. [DOI: 10.1159/000490943] [PMID: 30179864]">Paton 2018</a>; <a href="./references#CD013201-bbs2-0138" title="PatonMC , AllisonBJ , FaheyMC , LiJ , SutherlandAE , PhamY , et al. Umbilical cord blood versus mesenchymal stem cells for inflammation-induced preterm brain injury in fetal sheep. Pediatric Research2019;86:165-73. [DOI: 10.1038/s41390-019-0366-z] [PMID: 30858474]">Paton 2019</a>). The other important aspect of EoP is a subtle injury to cerebral grey matter (<a href="./references#CD013201-bbs2-0058" title="FleissB , GressensP , StolpH . Cortical gray matter injury in encephalopathy of prematurity: link to neurodevelopmental disorders. Frontiers in Neurology2020;11:575. [DOI: 10.3389/fneur.2020.00575] [PMID: 32765390]">Fleiss 2020</a>; <a href="./references#CD013201-bbs2-0185" title="VolpeJJ . Brain injury in premature infants: a complex amalgam of destructive and developmental disturbances. Lancet Neurology2009;8(1):110-24. [DOI: 10.1016/S1474-4422(08)70294-1] [PMID: 19081519]">Volpe 2009b</a>). γ‐Aminobutyric acid (GABA)‐ergic interneurons are rapidly developing during the third trimester in human pregnancies and this process continues several months after birth (<a href="./references#CD013201-bbs2-0096" title="LimL , MiD , LlorcaA , Marin O. Development and functional diversification of cortical interneurons. Neuron2018;100(2):294-313. [DOI: 10.1016/j.neuron.2018.10.009] [PMID: 30359598]">Lim 2018</a>). It is believed that maturational arrest and function of interneurons may be the underlying cause of behavioural deficits, such as attention deficit disorders, autism spectrum disorder, and socialisation problems. These problems tend to be important in children born extremely preterm (<a href="./references#CD013201-bbs2-0058" title="FleissB , GressensP , StolpH . Cortical gray matter injury in encephalopathy of prematurity: link to neurodevelopmental disorders. Frontiers in Neurology2020;11:575. [DOI: 10.3389/fneur.2020.00575] [PMID: 32765390]">Fleiss 2020</a>; <a href="./references#CD013201-bbs2-0103" title="MarinO . Interneuron dysfunction in psychiatric disorders. Nature Reviews Neuroscience2012;13:107-20. [DOI: 10.1038/nrn3155] [PMID: 22251963]">Marin 2012</a>). The only animal study published so far on the effect of MSC treatment on interneuron development in EoP model demonstrated partial recovery in social behaviour and restoration of parvalbumin‐positive interneurons, vasoactive intestinal polypeptide (VIP)‐positive cells in the cortex, and somatostatin (SST)‐positive cells in the hippocampus (<a href="./references#CD013201-bbs2-0175" title="VaesJE , KosmeijerCM , KaalM , vanVlietR , BrandtMJ , BendersMJ , et al. Regenerative therapies to restore interneuron disturbances in experimental models of encephalopathy of prematurity. International Journal of Molecular Sciences2020;22(1):211. [DOI: 10.3390/ijms22010211] [PMID: 33379239]">Vaes 2020</a>). Despite the few animal studies available at present stem cells seem to be a promising treatment strategy for EoP. </p> <p>Preterm infants with intraventricular haemorrhage (IVH) are at higher risk for white matter damage resulting in cerebral palsy and cognitive‐behavioural disorders (<a href="./references#CD013201-bbs2-0100" title="LuuTM , MentLR , SchneiderKC , KatzKH , AllanWC , VohrBR . Lasting effects of preterm birth and neonatal brain hemorrhage at 12 years of age. Pediatrics2009;123(3):1037-44. [DOI: 10.1542/peds.2008-1162] [PMID: 19255037]">Luu 2009</a>). Currently, no treatment is available for white matter damage following IVH. It has been suggested that the haemorrhage originates in the GM and evolves into IVH with further rupture of the ventricular ependyma (<a href="./references#CD013201-bbs2-0024" title="BallabhP . Pathogenesis and prevention of intraventricular hemorrhage. Clinics in Perinatology2014;41(1):47-67. [DOI: 10.1016/j.clp.2013.09.007] [PMID: 24524446]">Ballabh 2014</a>). Periventricular tissue is characterised by high presence of preoligodendrocytes, which progressively differentiate to mature oligodendrocyte. This process is particularly active between weeks 23 and 35 of gestation (<a href="./references#CD013201-bbs2-0020" title="BackSA , LuoNL , BorensteinNS , LevineJM , VolpeJJ , KinneyHC . Late oligodendrocyte progenitors coincide with the developmental window of vulnerability for human perinatal white matter injury. Journal of Neuroscience2001;21(4):1302-12. [PMID: 11160401]">Back 2001</a>; <a href="./references#CD013201-bbs2-0087" title="KhwajaO , VolpeJJ . Pathogenesis of cerebral white matter injury of prematurity. Archives of Disease in Childhood. Fetal and Neonatal Edition2008;93(2):F153-61. [DOI: 10.1136/adc.2006.108837] [PMID: 18296574]">Khwaja 2008</a>). Upon injury, OPCs migrate to the area of damage and differentiate to oligodendrocyte to restore myelination (<a href="./references#CD013201-bbs2-0033" title="BonfantiE , GelosaP , FumagalliM , DimouL , ViganòF , TremoliE , et al. The role of oligodendrocyte precursor cells expressing the GPR17 receptor in brain remodeling after stroke. Cell Death and Disease2017;8(6):e2871. [PMID: 28594400]">Bonfanti 2017</a>). However, following a neurological insult, the remyelination potential of resident OPCs is exhausted (<a href="./references#CD013201-bbs2-0179" title="vanVelthovenCT , KavelaarsA , HeijnenCJ . Mesenchymal stem cells as a treatment for neonatal ischemic brain damage. Pediatric Research2012;71(4-2):474-81. [DOI: 10.1038/pr.2011.64] [PMID: 22430383]">van Velthoven 2012</a>). In a rat model of hypoxic‐ischaemic brain injury, OPCs (differentiated from mouse embryonic stem cells (ESC)) migrated to the site of injury, differentiated into myelin‐producing oligodendrocyte, dampened neuronal apoptosis, and stimulated endogenous NSC proliferation (<a href="./references#CD013201-bbs2-0041" title="ChenLX , MaSM , ZhangP , FanZC , XiongM , ChengGQ , et al. Neuroprotective effects of oligodendrocyte progenitor cell transplantation in premature rat brain following hypoxic-ischemic injury. PLOS One2015;10(3):e0115997. [PMID: 25790286]">Chen 2015</a>). Animal studies suggest that both acute hypoxic‐ischaemic insult and IVH may arrest maturation of the pro‐oligodendrocytes, resulting in hypomyelination of brain white matter and subsequent loss of brain grey matter (<a href="./references#CD013201-bbs2-0053" title="DummulaK , VinukondaG , ChuP , XingY , HuF , MailkS , et al. Bone morphogenetic protein inhibition promotes neurological recovery after intraventricular hemorrhage. Journal of Neuroscience2011;31(34):12068-82. [DOI: 10.1523/JNEUROSCI.0013-11.2011] [PMID: 21865450]">Dummula 2011</a>; <a href="./references#CD013201-bbs2-0161" title="SegoviaKN , McClureM , MoravecM , LuoNL , WanY , GongX , et al. Arrested oligodendrocyte lineage maturation in chronic perinatal white matter injury. Annals of Neurology2008;63(4):520-30. [DOI: 10.1002/ana.21359] [PMID: 18393269]">Segovia 2008</a>). NSCs residing in the GM are therefore particularly vulnerable in preterm infants at risk of GMH (<a href="./references#CD013201-bbs2-0048" title="DawesWJ , ZhangX , FancySP , RowitchD , MarinoS . Moderate-grade germinal matrix haemorrhage activates cell division in the neonatal mouse subventricular zone. Developmental Neuroscience2016;38(6):430-44. [DOI: 10.1159/000455839] [PMID: 28343214]">Dawes 2016</a>; <a href="./references#CD013201-bbs2-0059" title="FuentealbaLC , ObernierK , Alvarez-BuyllaA . Adult neural stem cells bridge their niche. Cell Stem Cell2012;10(6):698-708. [DOI: 10.1016/j.stem.2012.05.012] [PMID: 22704510]">Fuentealba 2012</a>). Currently, no strategies to prevent WMI are known. </p> <p>The first use of stem cells for intracranial bleeding was proposed in adult animals: NSCs derived from mouse ESCs were transplanted into 10 adult rats with collagenase‐induced intracerebral haemorrhage (<a href="./references#CD013201-bbs2-0124" title="NonakaM , YoshikawaM , NishimuraF , YokotaH , KimuraH , HirabayashiH , et al. Intraventricular transplantation of embryonic stem cell-derived neural stem cells in intracerebral hemorrhage rats. Neurological Research2004;26(3):265-72. [DOI: 10.1179/016164104225014049] [PMID: 15142318]">Nonaka 2004</a>). Subsequent studies focused on the neuroprotective effects of MSCs. In the same animal model of intracerebral haemorrhage, administration of umbilical cord‐derived MSCs resulted in nerve fibre remyelination and axonal regeneration, and better neurological recovery compared to vehicle‐treated animals (<a href="./references#CD013201-bbs2-0098" title="LiuAM , LuG , TsangKS , LiG , WuY , HuangZS , et al. Umbilical cord-derived mesenchymal stem cells with forced expression of hepatocyte growth factor enhance remyelination and functional recovery in a rat intracerebral hemorrhage model. Neurosurgery2010;67(2):357-65; discussion 365-6. [DOI: 10.1227/01.NEU.0000371983.06278.B3] [PMID: 20644422]">Liu 2010</a>). Similar findings were discovered after NSC administration in non‐human primates with spinal injury (<a href="./references#CD013201-bbs2-0152" title="RosenzweigES , BrockJH , LuP , KumamaruH , SalegioEA , KadoyaK , et al. Restorative effects of human neural stem cell grafts on the primate spinal cord. Nature Medicine2018;24(4):484-90. [DOI: 10.1038/nm.4502] [PMID: 29480894]">Rosenzweig 2018</a>). The effects of umbilical cord blood MSCs and MNCs have been explored in small and large animals with severe IVH (<a href="./references#CD013201-bbs2-0014" title="AhnSY , ChangYS , SungDK , SungSI , YooHS , ImGH , et al. Optimal route for mesenchymal stem cells transplantation after severe intraventricular hemorrhage in newborn rats. PLOS One2015;10(7):e0132919. [DOI: 10.1371/journal.pone.0132919] [PMID: 26208299]">Ahn 2015</a>; <a href="./references#CD013201-bbs2-0019" title="AridasJD , McDonaldCA , PatonMC , YawnoT , SutherlandAE , NitsosI , et al. Cord blood mononuclear cells prevent neuronal apoptosis in response to perinatal asphyxia in the newborn lamb. Journal of Physiology2016;594(5):1421-35. [DOI: 10.1113/JP271104] [PMID: 26527561]">Aridas 2016</a>). In rat pups with severe IVH, administration of both intracerebral and intravenous MSCs resulted in attenuation of PHVD, better myelination, and improvement on behavioural tests (<a href="./references#CD013201-bbs2-0014" title="AhnSY , ChangYS , SungDK , SungSI , YooHS , ImGH , et al. Optimal route for mesenchymal stem cells transplantation after severe intraventricular hemorrhage in newborn rats. PLOS One2015;10(7):e0132919. [DOI: 10.1371/journal.pone.0132919] [PMID: 26208299]">Ahn 2015</a>). Subsequent studies showed that early MSC administration resulted in greater brain damage recovery (<a href="./references#CD013201-bbs2-0133" title="ParkWS , SungSI , AhnSY , SungDK , ImGH , YooHS , et al. Optimal timing of mesenchymal stem cell therapy for neonatal intraventricular hemorrhage. Cell Transplantation2016;25(6):1131-44. [DOI: 10.3727/096368915X689640] [PMID: 26440762]">Park 2016</a>). Even a low‐grade GM‐IVH may impair normal oligodendrogenesis by significantly reducing the number of oligodendrocytes in the cortex, whereas postnatal neurogenesis per se did not seem to be affected (<a href="./references#CD013201-bbs2-0048" title="DawesWJ , ZhangX , FancySP , RowitchD , MarinoS . Moderate-grade germinal matrix haemorrhage activates cell division in the neonatal mouse subventricular zone. Developmental Neuroscience2016;38(6):430-44. [DOI: 10.1159/000455839] [PMID: 28343214]">Dawes 2016</a>). </p> <p>Regenerative cells do not exert their therapeutic benefit by engrafting into the host tissue, but rather through the release of paracrine effects (<a href="./references#CD013201-bbs2-0072" title="HodgkinsonCP , BarejaA , GomezJA , DzauVJ . Emerging concepts in paracrine mechanisms in regenerative cardiovascular medicine and biology. Circulation Research2016;118(1):95-107. [DOI: 10.1161/CIRCRESAHA.115.305373] [PMID: 26837742]">Hodgkinson 2016</a>). They promote axon and dendrite growth by secreting mitogenic growth factors (brain‐derived neurotrophic factor (BDNF), stromal cell‐derived factor‐1 (SDF‐1), nerve growth factor (NGF)) known to enhance proliferation, migration, and differentiation of native neuronal progenitor/stem cells (<a href="./references#CD013201-bbs2-0040" title="ChenL , TredgetEE , WuPY , WuY . Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLOS One2008;3(4):e1886. [DOI: 10.1371/journal.pone.0001886] [PMID: 18382669]">Chen 2008</a>; <a href="./references#CD013201-bbs2-0042" title="ChoppM , LiY . Treatment of neural injury with marrow stromal cells. Lancet Neurology2002;1(2):92-100. [PMID: 12849513]">Chopp 2002</a>; <a href="./references#CD013201-bbs2-0061" title="GageFH , TempleS . Neural stem cells: generating and regenerating the brain. Neuron2013;80(3):588-601. [DOI: 10.1016/j.neuron.2013.10.037] [PMID: 24183012]">Gage 2013</a>; <a href="./references#CD013201-bbs2-0113" title="MurphyMB , MoncivaisK , CaplanAI . Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Experimental &amp; Molecular Medicine2013;45(11):e54. [DOI: 10.1038/emm.2013.94] [PMID: 24232253]">Murphy 2013</a>). Moreover, cell‐based therapies can attenuate inflammation (IL‐1β, interferon‐γ (IFNγ)) by modulating the function of immune cells, such as T and B cells, macrophages, and dendritic cells (<a href="./references#CD013201-bbs2-0034" title="BoshuizenMC , SteinbergGK . Stem cell-based immunomodulation after stroke: effects on brain repair processes. Stroke2018;49(6):1563-70. [PMID: 29724892]">Boshuizen 2018</a>; <a href="./references#CD013201-bbs2-0081" title="IyerSS , RojasM . Anti-inflammatory effects of mesenchymal stem cells: novel concept for future therapies. Expert Opinion on Biological Therapy2008;8(5):569-81. [DOI: 10.1517/14712598.8.5.569] [PMID: 18407762]">Iyer 2008</a>). They enhance angiogenesis (vascular endothelial growth factor (VEGF), IGF‐1), regulate reactive oxygen species production, and may even transfer organelles to injured cells (i.e. mitochondria) (<a href="./references#CD013201-bbs2-0034" title="BoshuizenMC , SteinbergGK . Stem cell-based immunomodulation after stroke: effects on brain repair processes. Stroke2018;49(6):1563-70. [PMID: 29724892]">Boshuizen 2018</a>; <a href="./references#CD013201-bbs2-0040" title="ChenL , TredgetEE , WuPY , WuY . Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLOS One2008;3(4):e1886. [DOI: 10.1371/journal.pone.0001886] [PMID: 18382669]">Chen 2008</a>; <a href="./references#CD013201-bbs2-0080" title="IslamMN , DasSR , EminMT , WeiM , SunL , WestphalenK , et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nature Medicine2012;18(5):759-65. [DOI: 10.1038/nm.2736] [PMID: 22504485]">Islam 2012</a>; <a href="./references#CD013201-bbs2-0113" title="MurphyMB , MoncivaisK , CaplanAI . Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Experimental &amp; Molecular Medicine2013;45(11):e54. [DOI: 10.1038/emm.2013.94] [PMID: 24232253]">Murphy 2013</a>). Hence, regenerative cells are emerging as potential treatment strategies for complex diseases such as GM‐IVH with subsequent impaired brain development. </p> </section> <section id="CD013201-sec-0017"> <h3 class="title" id="CD013201-sec-0017">Why it is important to do this review</h3> <p>This review is important to conduct as regenerative cells might be an effective intervention for prevention and treatment of GM‐IVH and EoP, which are amongst the most severe morbidities in preterm infants. To date, US clinical trials studying the safety, feasibility, or efficacy (or a combination of these) of regenerative cells have been registered for bronchopulmonary dysplasia (BPD), hypoxic‐ischaemic encephalopathy, hypoplastic left heart syndrome, and GM‐IVH. The most widespread tissue used to derive regenerative cells is the umbilical cord (<a href="./references#CD013201-bbs2-0107" title="MitsialisSA , KourembanasS . Stem cell-based therapies for the newborn lung and brain: possibilities and challenges. Seminars in Perinatology2016;40(3):138-51. [DOI: 10.1053/j.semperi.2015.12.002] [PMID: 26778234]">Mitsialis 2016</a>; <a href="./references#CD013201-bbs2-0194" title="YoonSY , ChangS , ParkWS . Stem cells for neonatal brain disorders. Neonatology2016;109(4):377-83. [DOI: 10.1159/000444905] [PMID: 27251746]">Yoon 2016</a>). Although MSCs dominate as the cell type, a few trials are evaluating neural progenitor cells, MNCs, and placenta/cord blood cells (<a href="./references#CD013201-bbs2-0116" title="NCT02434965. Autologous cord blood and human placental derived stem cells in neonates with severe hypoxic-ischemic encephalopathy (HPDSC+HIE). clinicaltrials.gov/ct2/show/NCT02434965 (first received 21 June 2018).">NCT02434965</a>; <a href="./references#CD013201-bbs2-0119" title="NCT02854579. Neural progenitor cell and paracrine factors to treat hypoxic-ischemic encephalopathy. clinicaltrials.gov/ct2/show/NCT02854579 (first received 3 August 2016).">NCT02854579</a>; <a href="./references#CD013201-bbs2-0120" title="NCT02999373. Prevention of preterm infection by autologous umbilical cord blood mononuclear cells therapy. clinicaltrials.gov/ct2/show/NCT02999373 (first received 21 December 2016).">NCT02999373</a>). </p> <p>The efficacy and safety of regenerative cell administration have been assessed in several systematic reviews and meta‐analyses. For instance, one meta‐analysis across different disciplines evaluated the safety of MSCs (eight studies including 321 adults), finding no association between acute infusional toxicity, organ system complications, infection, death, or malignancy (<a href="./references#CD013201-bbs2-0093" title="LaluMM , McIntyreL , PuglieseC , FergussonD , WinstonBW , MarshallJC , et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLOS One2012;7(10):e47559. [DOI: 10.1371/journal.pone.0047559] [PMID: 23133515]">Lalu 2012</a>). However, the risk of potential tumourigenicity related to MSC‐based interventions needs to be further elucidated (<a href="./references#CD013201-bbs2-0025" title="BarkholtL , FloryE , JekerleV , Lucas-SamuelS , AhnertP , BissetL , et al. Risk of tumorigenicity in mesenchymal stromal cell-based therapies – bridging scientific observations and regulatory viewpoints. Cytotherapy2013;15(7):753-9. [DOI: 10.1016/j.jcyt.2013.03.005] [PMID: 23602595]">Barkholt 2013</a>). The Cochrane Review entitled "Stem cell transplantation for ischaemic stroke" included three small trials in adults (<a href="./references#CD013201-bbs2-0032" title="BoncoraglioGB , RanieriM , BersanoA , ParatiEA , Del GiovaneC . Stem cell transplantation for ischemic stroke. Cochrane Database of Systematic Reviews2019, Issue 5. Art. No: CD007231. [DOI: 10.1002/14651858.CD007231.pub3]">Boncoraglio 2019</a>). For newborns, one Cochrane Review has been conducted on MSC for prevention and treatment of BPD amongst preterm infants (<a href="./references#CD013201-bbs2-0144" title="PierroM , ThebaudB , SollR . Mesenchymal stem cells for the prevention and treatment of bronchopulmonary dysplasia in preterm infants. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD011932. [DOI: 10.1002/14651858.CD011932.pub2]">Pierro 2017</a>). Early‐phase trials have been conducted (or are underway) on the use of MSCs or cord blood cells (or both) for BPD, severe IVH (<a href="./references#CD013201-bbs2-0006" title="NCT02274428. Phase 1 clinical trial of PNEUMOSTEM® treatment in premature infants with intraventricular hemorrhage. clinicaltrials.gov/ct2/show/NCT02274428 (first received 24 October 2014). ">NCT02274428</a>), and hypoxic‐ischaemic encephalopathy (<a href="./references#CD013201-bbs2-0045" title="CottenCM , MurthaAP , GoldbergRN , GrotegutCA , SmithPB , GoldsteinRF , et al. Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy. Journal of Pediatrics2014;164(5):973-9.e1. [DOI: 10.1016/j.jpeds.2013.11.036] [PMID: 24388332]">Cotten 2014</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013201-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013201-sec-0018"></div> <p>To evaluate the benefits and harms of stem cell‐based interventions for prevention or treatment of GM‐IVH and EoP in preterm infants. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013201-sec-0019" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013201-sec-0019"></div> <section id="CD013201-sec-0020"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013201-sec-0021"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs), quasi‐RCTs, and cluster trials. We excluded cross‐over trials. </p> </section> <section id="CD013201-sec-0022"> <h4 class="title">Types of participants</h4> <p>Prevention studies:</p> <p> <ul id="CD013201-list-0019"> <li> <p>extremely preterm infants (less than 28 weeks' gestation), 24 hours of age or less, without ultrasound diagnosis of GM‐IVH or EoP. </p> </li> </ul> </p> <p>Treatment studies:</p> <p> <ul id="CD013201-list-0020"> <li> <p>preterm infants (less than 37 weeks' gestation), of any postnatal age, with ultrasound diagnosis of GM‐IVH (GM‐IVH treatment studies). We included infants with ventricular shunt; </p> </li> <li> <p>preterm infants (less than 37 weeks' gestation), of any postnatal age, with diagnosis of EoP (e.g. cystic PVL, dWMI, grey matter injury) (EoP treatment studies). </p> </li> </ul> </p> </section> <section id="CD013201-sec-0023"> <h4 class="title">Types of interventions</h4> <p>For each of the population described above, we conducted the following comparisons.</p> <p> <ul id="CD013201-list-0021"> <li> <p><b>Comparison 1:</b> stem cell‐based interventions (any type) compared to control (placebo or no treatment) </p> </li> <li> <p><b>Comparison 2:</b> use of MSCs of type (e.g. number of doses or passages) or source (e.g. autologous versus allogeneic, bone marrow versus cord) versus MSCs of other type or source </p> </li> <li> <p><b>Comparison 3:</b> use of stem cell‐based interventions other than MSCs of type (e.g. MNCs, OPCs, NSCs, haematopoietic stem cells, iPSCs) or source (e.g. autologous versus allogeneic, bone marrow versus cord) versus stem cell‐based interventions other than MSCs of other type or source </p> </li> <li> <p><b>Comparison 4:</b> MSCs versus stem cell‐based interventions other than MSCs </p> </li> </ul> </p> <p>We included all types of transplantation regardless of cell source (bone marrow, cord blood versus Wharton's jelly, placenta, adipose tissue, peripheral blood), type of graft (autologous or allogeneic), route of administration (intravenous or intraventricular, e.g. in infants with PHVD and ventricular shunt), and dose. We excluded stem cell‐derived cerebral organoids (<a href="./references#CD013201-bbs2-0051" title="Di LulloE , KriegsteinAR . The use of brain organoids to investigate neural development and disease. Nature Reviews. Neuroscience2017;18(10):573-84. [DOI: 10.1038/nrn.2017.107] [PMID: 28878372]">Di Lullo 2017</a>). </p> <p>Although procedures to increase placental transfusion such as delayed cord clamping and cord milking are potential sources of (limited numbers of) stem cells, a separate Cochrane Review has addressed these interventions (<a href="./references#CD013201-bbs2-0149" title="RabeH , GyteGM , Díaz-RosselloJL , DuleyL . Effect of timing of umbilical cord clamping and other strategies to influence placental transfusion at preterm birth on maternal and infant outcomes. Cochrane Database of Systematic Reviews2019, Issue 9. Art. No: CD003248. [DOI: 10.1002/14651858.CD003248.pub4]">Rabe 2019</a>). </p> <p>Characteristic of these interventions are specified in <a href="#CD013201-sec-0040">Subgroup analysis and investigation of heterogeneity</a>. </p> </section> <section id="CD013201-sec-0024"> <h4 class="title">Types of outcome measures</h4> <section id="CD013201-sec-0025"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013201-list-0022"> <li> <p>All‐cause neonatal mortality (mortality less than 28 days of age)</p> </li> <li> <p>Major neurodevelopmental disability: cerebral palsy, developmental delay (Bayley Mental Developmental Index (<a href="./references#CD013201-bbs2-0027" title="BayleyN . Bayley Scales of Infant Development. 2nd edition. San Antonio (TX): The Psychological Corporation, 1993.">Bayley 1993</a>; <a href="./references#CD013201-bbs2-0028" title="BayleyN . Bayley Scales of Infant and Toddler Development. San Antonio (TX): Harcourt Assessment, 2006.">Bayley 2006</a>) or Griffiths Mental Development Scale (<a href="./references#CD013201-bbs2-0067" title="GriffithsR . The Abilities of Babies: a Study in Mental Measurement. New York (NY): McGraw-Hill Book Co Inc, 1954.">Griffiths 1954</a>) assessment greater than two standard deviations (SDs) below the mean), intellectual impairment (intelligence quotient (IQ) greater than two SDs below the mean), blindness (vision less than 6/60 in both eyes), or sensorineural deafness requiring amplification (<a href="./references#CD013201-bbs2-0082" title="JacobsSE , BergM , HuntR , Tarnow-MordiWO , InderTE , DavisPG . Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database of Systematic Reviews2013, Issue 1. Art. No: CD003311. [DOI: 10.1002/14651858.CD003311.pub3]">Jacobs 2013</a>). We planned to separately assess data on children aged 18 to 24 months and those aged three to five years </p> </li> <li> <p>For prevention trials: GM‐IVH: any grade; severe IVH grade 3 to 4 (for prevention studies only) (<a href="./references#CD013201-bbs2-0132" title="PapileLA , BursteinJ , BursteinR , KofflerH . Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. Journal of Pediatrics1978;92(4):529-34. [PMID: 305471]">Papile 1978</a>) </p> </li> <li> <p>For prevention trials: EoP (<a href="./references#CD013201-bbs2-0182" title="VolpeJJ . Encephalopathy of prematurity includes neuronal abnormalities. Pediatrics2005;116(1):221-5. [DOI: 10.1542/peds.2005-0191] [PMID: 15995055]">Volpe 2005</a>) </p> </li> <li> <p>For GM‐IVH treatment trials: extension of pre‐existing non‐severe GM‐IVH (e.g. grade 1 to 2) to severe IVH (e.g. grade 3 to 4) (yes/no) (<a href="./references#CD013201-bbs2-0132" title="PapileLA , BursteinJ , BursteinR , KofflerH . Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. Journal of Pediatrics1978;92(4):529-34. [PMID: 305471]">Papile 1978</a>). Although the timing for neuroimaging might differ between trials, within each trial the intervals schedule must be identical in the intervention and control groups. If both ultrasound and MRI are available for the same infants, we plan to refer to the modality with the highest IVH grade </p> </li> </ul> </p> </section> <section id="CD013201-sec-0026"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013201-list-0023"> <li> <p>All‐cause mortality before first hospital discharge</p> </li> <li> <p>Cerebellar haemorrhage on brain ultrasound in the first month of life (yes/no; <a href="./references#CD013201-bbs2-0065" title="GraçaAM , GeraldoAF , CardosoK , CowanFM . Preterm cerebellum at term age: ultrasound measurements are not different from infants born at term. Pediatric Research2013;74(6):698-704. [DOI: 10.1038/pr.2013.154] [PMID: 24002327]">Graça 2013</a>) </p> </li> <li> <p>Cystic PVL on brain ultrasound in the first month of life</p> </li> <li> <p>MRI abnormalities at term equivalent age (yes/no), defined as white matter lesions (i.e. cavitations; <a href="./references#CD013201-bbs2-0154" title="RutherfordMA , SupramaniamV , EderiesA , ChewA , BassiL , GroppoM , et al. Magnetic resonance imaging of white matter diseases of prematurity. Neuroradiology2010;52(6):505-21. [DOI: 10.1007/s00234-010-0700-y] [PMID: 20422407]">Rutherford 2010</a>), punctate lesions (<a href="./references#CD013201-bbs2-0044" title="CornetteLG , TannerSF , RamenghiLA , MiallLS , ChildsAM , ArthurRJ , et al. Magnetic resonance imaging of the infant brain: anatomical characteristics and clinical significance of punctate lesions. Archives of Disease in Childhood. Fetal and Neonatal Edition2002;86(3):F171-7. [PMID: 11978747]">Cornette 2002</a>), GM‐IVH (<a href="./references#CD013201-bbs2-0134" title="ParodiA , MoranaG , SeverinoMS , MalovaM , NataliziaAR , SanniaA , et al. Low-grade intraventricular hemorrhage: is ultrasound good enough?Journal of Maternal-fetal &amp; Neonatal Medicine2015;28(Suppl 1):2261-4. [DOI: 10.3109/14767058.2013.796162] [PMID: 23968243]">Parodi 2015</a>), or cerebellar haemorrhage (<a href="./references#CD013201-bbs2-0097" title="LimperopoulosC , BassanH , GauvreauK , Robertson RL Jr, SullivanNR , BensonCB , et al. Does cerebellar injury in premature infants contribute to the high prevalence of long-term cognitive, learning, and behavioral disability in survivors?Pediatrics2007;120(3):584-93. [DOI: 10.1542/peds.2007-1041] [PMID: 17766532]">Limperopoulos 2007</a>) </p> </li> <li> <p>Need for ventricular shunt in the first three months of life (yes/no)</p> </li> <li> <p>Duration of hospital stay (days)</p> </li> <li> <p>BPD/chronic lung disease: 28 days (<a href="./references#CD013201-bbs2-0122" title="National Institutes of Health. Report of workshop on bronchopulmonary dysplasia. In: NIH Publication No. 80-1660; 1978 December 4-6; Bethesda (MD). Washington (DC): National Institutes of Health, 1979.">NIH 1979</a>); 36 weeks' postmenstrual age (<a href="./references#CD013201-bbs2-0085" title="JobeAH , BancalariE . Bronchopulmonary dysplasia. American Journal of Respiratory and Critical Care Medicine2001;163(7):1723-9. [DOI: 10.1164/ajrccm.163.7.2011060] [PMID: 11401896]">Jobe 2001</a>); 'physiological definition' (<a href="./references#CD013201-bbs2-0188" title="WalshMC , YaoQ , GettnerP , HaleE , CollinsM , HensmanA , et al. Impact of a physiologic definition on bronchopulmonary dysplasia rates. Pediatrics2004;114(5):1305-11. [DOI: 10.1542/peds.2004-0204] [PMID: 15520112]">Walsh 2004</a>) </p> </li> <li> <p>Patent ductus arteriosus (that has been treated with cyclo‐oxygenase inhibitor or surgery) </p> </li> <li> <p>Necrotising enterocolitis (NEC; defined as Bell's stage II or greater) (<a href="./references#CD013201-bbs2-0029" title="BellMJ , TernbergJL , FeiginRD , KeatingJP , MarshallR , BartonL , et al. Neonatal necrotising enterocolitis. Therapeutic decisions based upon clinical staging. Annals of Surgery1978;187(1):1-7. [PMID: 413500]">Bell 1978</a>) </p> </li> <li> <p>Retinopathy of prematurity (ROP) in infants examined (all stages and severe (stage 3 or greater)) (<a href="./references#CD013201-bbs2-0077" title="Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Pediatrics1984;74(1):127-33. [PMID: 6547526]">ICROP 1984</a>) </p> </li> <li> <p>Tumour formation, any type, any location, detected by MRI or computed tomography (to assess risk of tumourigenicity of donor MSCs) </p> </li> <li> <p>Immune rejection or any serious adverse event (certain, probable, or possible according to the World Health Organization (WHO) probability scale). We planned to consider post‐hoc analyses for any unexpected adverse effects reported by these studies </p> </li> <li> <p>Each component of the composite outcome 'major neurodevelopmental disability' (see <a href="http://Primary outcomes" target="_blank">Primary outcomes</a>) </p> </li> </ul> </p> </section> </section> </section> <section id="CD013201-sec-0027"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013201-sec-0028"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Sweden Information Specialist revised search strategies for this iteration of the review to incorporate additional terminology necessary due to the inclusion of EoP. They searched the following databases in April 2022; we did not use date, language, or publication type limits: </p> <p> <ul id="CD013201-list-0024"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL), Issue 4, 2022;</p> </li> <li> <p>PubMed (1946 to 11 April 2022);</p> </li> <li> <p>Embase (Embase.com, Elsevier), (1947 to 11 April 2022);</p> </li> <li> <p>CINAHL (Cumulative Index to Nursing and Allied Health Literature) (EBSCOhost, 1982 to 11 April 2022). </p> </li> </ul> </p> <p>Full search strategies are available in <a href="./appendices#CD013201-sec-0068">Appendix 1</a>; search strategies used for the previous version of this review are in <a href="./appendices#CD013201-sec-0076">Appendix 2</a>. </p> <p>We searched the following clinical trials registries for ongoing and recently completed trials: </p> <p> <ul id="CD013201-list-0025"> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>); </p> </li> <li> <p>WHO International Trials Registry and Platform (ICTRP) (<a href="https://trialsearch.who.int/Default.aspx" target="_blank">trialsearch.who.int/Default.aspx</a>). </p> </li> </ul> </p> </section> <section id="CD013201-sec-0029"> <h4 class="title">Searching other resources</h4> <p>We reviewed the reference lists of all identified articles for relevant articles not identified in the primary search. We searched for errata or retractions from included studies published in full text on PubMed (<a href="http://www.ncbi.nlm.nih.gov/pubmed" target="_blank">www.ncbi.nlm.nih.gov/pubmed</a>). </p> </section> </section> <section id="CD013201-sec-0030"> <h3 class="title" id="CD013201-sec-0030">Data collection and analysis</h3> <p>We used the standard methods of Cochrane Neonatal, as described below.</p> <section id="CD013201-sec-0031"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MB, OR) independently screened title/abstracts and the full text of potentially relevant studies included based on title/abstract review. At any point in the screening process, disagreements between review authors were resolved by discussion or a third review author (DL). We independently assessed the eligibility of studies by filling out eligibility forms designed in accordance with the specified inclusion criteria. We excluded studies published only in abstract form unless the final results of the trial were reported and all necessary information could be ascertained from the abstract or from study authors, or both. We reviewed studies for relevance by assessing study design, types of participants, interventions provided, and outcome measures reported. We resolved disagreements by discussion and, if necessary, by consultation with a third review author (DL). We provided details of excluded studies in the <a href="./references#CD013201-sec-0087" title="">Characteristics of excluded studies</a> table, along with reasons for exclusion. We planned to contact trial authors if details of primary trials were unclear. </p> <p>We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="./references#CD013201-bbs2-0108" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006-12. [DOI: 10.1016/j.jclinepi.2009.06.005] [PMID: 19631508]">Moher 2009</a>), and <a href="./references#CD013201-sec-0087" title="">Characteristics of excluded studies</a> tables. </p> </section> <section id="CD013201-sec-0032"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (MB, OR) planned to independently extract data using a data extraction form integrated with a modified version of the Cochrane Effective Practice and Organisation of Care Group data collection checklist (<a href="./references#CD013201-bbs2-0043" title="Cochrane Effective Practice and Organisation of Care (EPOC). Data extraction and management. EPOC resources for review authors, 2017. epoc.cochrane.org/epoc-resources-review-authors (accessed prior to 17 January 2023).">Cochrane EPOC Group 2017</a>). We planned to pilot the form within the review team using a sample of included studies. </p> <p>We planned to extract the following characteristics from each included study.</p> <p> <ul id="CD013201-list-0026"> <li> <p>Administrative details: study author(s); published or unpublished; year of publication; year in which study was conducted; presence of vested interest; details of other relevant papers cited. </p> </li> <li> <p>Study: study design; type, duration, and completeness of follow‐up (e.g. greater than 80%); country and location of study; informed consent; ethics approval. </p> </li> <li> <p>Participants: sex, birth weight, gestational age, number of participants.</p> </li> <li> <p>Interventions: initiation, dose, and duration of MSC administration.</p> </li> <li> <p>Outcomes as mentioned above under <a href="#CD013201-sec-0024">Types of outcome measures</a>. </p> </li> </ul> </p> <p>We planned to resolve disagreements by discussion. We described ongoing studies identified by our search, when available, detailing the primary author, research question(s), methods, and outcome measures, together with an estimate of the reporting date, and we report them in the <a href="./references#CD013201-sec-0088" title="">Characteristics of ongoing studies</a> table. </p> <p>Should any queries have arisen, or in cases for which additional data were required, we planned to contact study investigators/authors for clarification. Two review authors (MB, OR) planned to use the Cochrane statistical tool for data entry (<a href="./references#CD013201-bbs2-0150" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>). We planned to replace any standard error of the mean (SEM) with the corresponding SD. </p> </section> <section id="CD013201-sec-0033"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (MB, OR) planned to independently assess risk of bias (low, high, or unclear) of all included trials using the Cochrane RoB 2 tool for the following domains (<a href="./references#CD013201-bbs2-0071" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). </p> <p> <ul id="CD013201-list-0027"> <li> <p>Sequence generation (selection bias).</p> </li> <li> <p>Allocation concealment (selection bias).</p> </li> <li> <p>Blinding of participants and personnel (performance bias).</p> </li> <li> <p>Blinding of outcome assessment (detection bias).</p> </li> <li> <p>Incomplete outcome data (attrition bias).</p> </li> <li> <p>Selective reporting (reporting bias).</p> </li> <li> <p>Any other bias.</p> </li> </ul> </p> <p>We planned to resolve any disagreements by discussion or by consultation with a third review author (AM). See <a href="./appendices#CD013201-sec-0077">Appendix 3</a> for a more detailed description of risk of bias for each domain. </p> </section> <section id="CD013201-sec-0034"> <h4 class="title">Measures of treatment effect</h4> <p>We planned to use risk ratios (RRs), risk differences (RDs), number needed to treat for an additional beneficial outcome (NNTBs) or number needed to treat for an additional harmful outcome (NNTHs) for categorical variables, and mean differences (MDs) for continuous variables. We planned to replace any within‐group SEM reported in a trial with its corresponding SD using the formula SD = SEM × √n, where n is the number of participants. We planned to report 95% confidence intervals (CIs) for each statistic. </p> </section> <section id="CD013201-sec-0035"> <h4 class="title">Unit of analysis issues</h4> <p>We planned to include all RCTs and quasi‐RCTs in which the unit of allocation was the individual infant. If we had found any cluster RCTs, we planned to adjust analysis for the designed effect using the method stated in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013201-bbs2-0071" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). </p> </section> <section id="CD013201-sec-0036"> <h4 class="title">Dealing with missing data</h4> <p>We planned to obtain a dropout rate for each study. If we had found a significant dropout rate (e.g. greater than 20%), we planned to contact the study author(s) to request additional data. We planned to perform a sensitivity analysis to evaluate the overall results with and without inclusion of studies with a significant dropout rate. If a study had reported outcomes only for participants completing the trial or only for participants who followed the protocol, we planned to contact study author(s) to ask them to provide additional information to facilitate an intention‐to‐treat analysis; in instances when this would not be possible, we planned to perform a complete‐case analysis. </p> </section> <section id="CD013201-sec-0037"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to assess clinical heterogeneity by comparing the distribution of important participant factors between trials and trial factors (randomisation concealment, blinding of outcome assessment, loss to follow‐up, treatment type, co‐interventions). We planned to assess statistical heterogeneity by examining the I² statistic (<a href="./references#CD013201-bbs2-0071" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>), a quantity that describes the proportion of variation in point estimates that is due to variability across studies rather than to sampling error. </p> <p>We planned to interpret the I² statistic as follows, as described by <a href="./references#CD013201-bbs2-0070" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327(7414):557-60. [DOI: 10.1136/bmj.327.7414.557] [PMID: 12958120]">Higgins 2003</a>. </p> <p> <ul id="CD013201-list-0028"> <li> <p>Less than 25%: no (none) heterogeneity.</p> </li> <li> <p>25% to 49%: low heterogeneity.</p> </li> <li> <p>50% to 74%: moderate heterogeneity.</p> </li> <li> <p>75% or greater: high heterogeneity.</p> </li> </ul> </p> <p>We planned to consider statistical heterogeneity to be substantial when the I² statistic was 50% or greater. In addition, we planned to use the Chi² test of homogeneity to determine the strength of evidence that heterogeneity was genuine. We planned to explore clinical variation across studies by comparing the distribution of participant‐important factors amongst trials and trial factors (randomisation concealment, blinding of outcome assessment, loss to follow‐up, treatment types, and co‐interventions). We planned to consider a threshold of P less than 0.1 as an indicator of whether there was heterogeneity (genuine variation in effect sizes). </p> </section> <section id="CD013201-sec-0038"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to examine the possibility of within‐study selective outcome reporting for each study included in the review. We planned to search for trial protocols of included trials through electronic sources such as PubMed, ClinicalTrials.gov, and the WHO ICTRP to assess whether outcome reporting was sufficiently complete and transparent. We planned to investigate publication using funnel plots if we could include 10 or more clinical trials in the systematic review (<a href="./references#CD013201-bbs2-0054" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34. [PMID: 9310563]">Egger 1997</a>; <a href="./references#CD013201-bbs2-0071" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook.">Higgins 2021</a>). </p> </section> <section id="CD013201-sec-0039"> <h4 class="title">Data synthesis</h4> <p>We planned to perform statistical analyses according to the recommendations of Cochrane Neonatal (<a href="http://neonatal.cochrane.org/en/index.html" target="_blank">neonatal.cochrane.org/en/index.html</a>), using <a href="./references#CD013201-bbs2-0150" title="Review Manager Web (RevMan Web). Version 4.12.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.">RevMan Web 2022</a>. We planned to analyse all infants randomised on an intention‐to‐treat basis. We planned to analyse treatment effects in the individual trials. We planned to use a fixed‐effect model to combine the data. For all meta‐analyses, we planned to synthesise data using RR, RD, NNTB, NNTH, MD, and 95% CI. We planned to analyse and interpret individual trials separately when we judged meta‐analysis to be inappropriate. </p> </section> <section id="CD013201-sec-0040"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to perform the following subgroup analyses.</p> <p>For MSC trials:</p> <p> <ul id="CD013201-list-0029"> <li> <p>gestational age: extremely preterm infants (less than 28 weeks' gestation), very preterm infants (28 to 31+6 weeks' gestation); </p> </li> <li> <p>chronological age: less than 3 days, 3 days or greater;</p> </li> <li> <p>co‐intervention: with/without cooling;</p> </li> <li> <p>MSC source: bone marrow, cord blood versus Wharton's Jelly, placenta, adipose tissue, peripheral blood; </p> </li> <li> <p>type of graft: autologous or allogeneic;</p> </li> <li> <p>preconditioned (yes, no);</p> </li> <li> <p>fresh or frozen and thawed;</p> </li> <li> <p>MSC dose: less than 2 × 10⁷/kg; 2 × 10⁷/kg or greater;</p> </li> <li> <p>number of doses: multiple or single administration; and</p> </li> <li> <p>passage number (i.e. removing cells from a culture flask and plating them into more culture flasks, see <a href="#CD013201-sec-0015">Description of the intervention</a>): less than three; three to six; greater than six. </p> </li> </ul> </p> <p>For other cell‐based interventions:</p> <p> <ul id="CD013201-list-0030"> <li> <p>gestational age: extremely preterm infants (less than 28 weeks' gestation), very preterm infants (28 to 31+6 weeks' gestation); </p> </li> <li> <p>chronological age: less than three days, three days or greater;</p> </li> <li> <p>co‐intervention: with/without cooling;</p> </li> <li> <p>cell source: bone marrow, cord blood, peripheral blood, placenta;</p> </li> <li> <p>type of graft: autologous or allogeneic;</p> </li> <li> <p>fresh or frozen and thawed; and</p> </li> <li> <p>number of doses: multiple or single administration.</p> </li> </ul> </p> </section> <section id="CD013201-sec-0041"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to conduct sensitivity analyses to explore the effects of the methodological quality of trials, checking to ascertain whether studies with high risk of bias might overestimate the effects of treatment. Differences in study design of included trials might affect the results of the systematic review. We planned to perform a sensitivity analysis to compare the effects of MSCs in truly randomised trials as opposed to quasi‐randomised trials. </p> </section> <section id="CD013201-sec-0042"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We planned to use the GRADE approach to assess the certainty of evidence for the following (clinically relevant) outcomes (<a href="./references#CD013201-bbs2-0158" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from gdt.guidelinedevelopment.org/app/handbook/handbook.html.">Schünemann 2013</a>): </p> <p> <ul id="CD013201-list-0031"> <li> <p>all‐cause neonatal mortality (mortality less than 28 days of age);</p> </li> <li> <p>major neurodevelopmental disability: cerebral palsy, developmental delay (Bayley Mental Developmental Index or Griffiths Mental Development Scale assessment greater than two SDs below the mean), intellectual impairment (IQ greater than two SDs below the mean), blindness (vision less than 6/60 in both eyes), or sensorineural deafness requiring amplification; </p> </li> <li> <p>severe IVH grade 3 to 4, for prevention studies;</p> </li> <li> <p>all‐cause mortality before first hospital discharge;</p> </li> <li> <p>EoP (<a href="./references#CD013201-bbs2-0182" title="VolpeJJ . Encephalopathy of prematurity includes neuronal abnormalities. Pediatrics2005;116(1):221-5. [DOI: 10.1542/peds.2005-0191] [PMID: 15995055]">Volpe 2005</a>), for prevention studies; </p> </li> <li> <p>ROP in infants examined (stage 3 or greater);</p> </li> <li> <p>immune rejection or any serious adverse event (certain, probable, or possible according to the WHO probability scale). </p> </li> </ul> </p> <p>Two review authors (MB; OR) planned to independently assess the certainty of evidence for each of the seven outcomes above. We planned to consider evidence from RCTs as high certainty but to downgrade the evidence one level for serious (or two levels for very serious) limitations based upon the following: design (risk of bias), consistency across studies, directness of evidence, precision of estimates, and presence of publication bias. We planned to use <a href="./references#CD013201-bbs2-0066" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), accessed 16 March 2018. Available at gradepro.org.">GRADEpro GDT</a> to create a summary of findings table to report the certainty of evidence. </p> <p>The GRADE approach results in an assessment of the certainty of a body of evidence for one of four grades. </p> <p> <ul id="CD013201-list-0032"> <li> <p>High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate certainty: we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low certainty: our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low certainty: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013201-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013201-sec-0043"></div> <section id="CD013201-sec-0044"> <h3 class="title">Description of studies</h3> <p>We have provided results of the search for this review update in the study flow diagram (<a href="#CD013201-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD013201-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="original image" data-id="CD013201-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013201.pub3/media/CDSR/CD013201/image_n/nCD013201-FIG-01.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <section id="CD013201-sec-0045"> <h4 class="title">Results of the search</h4> <p>The search identified 723 references (673 from databases; 50 from trial registries). After removing 119 duplicates, 604 references were available for screening. We excluded 592 references based on title/abstract and reviewed 12 full‐texts (nine full studies; three ongoing studies). We identified no studies for inclusion in this review, but the three ongoing studies may prove eligible for a subsequent update (<a href="./references#CD013201-bbs2-0010" title="ACTRN12619001637134. Autologous transplantation of umbilical cord blood derived stem cells in extreme preterm infants: protocol for a safety and feasibility study. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=378721 (first received 11 November 2019). [ACTRN: 12619001637134] MalhotraA , NovakI , MillerSL , JenkinG . Autologous transplantation of umbilical cord blood-derived cells in extreme preterm infants: protocol for a safety and feasibility study. BMJ Open2020;10(5):e036065. [DOI: 10.1136/bmjopen-2019-036065] [PMID: 32398336]">ACTRN12619001637134</a>; <a href="./references#CD013201-bbs2-0011" title="NCT02890953. Efficacy and safety evaluation of Pneumostem® versus a control group for treatment of IVH in premature infants (phase 2a). clinicaltrials.gov/ct2/show/NCT02890953 (first received 7 September 2016). ">NCT02890953</a>; <a href="./references#CD013201-bbs2-0012" title="NCT04440670. Effect of autologous cord blood mononuclear cells for prevention of bronchopulmonary dysplasia in extremely preterm neonates: a placebo-controlled randomized multicenter trial. clinicaltrials.gov/show/NCT04440670 (first received 22 June 2020). ">NCT04440670</a>). For details of excluded studies see <a href="./references#CD013201-sec-0088" title="">Characteristics of ongoing studies</a> table. </p> </section> <section id="CD013201-sec-0046"> <h4 class="title">Included studies</h4> <p>We identified no trials that matched our inclusion criteria.</p> </section> <section id="CD013201-sec-0047"> <h4 class="title">Excluded studies</h4> <p>We identified nine studies and excluded them all at full‐text screening: five were not randomised trials (<a href="./references#CD013201-bbs2-0002" title="AhnSY , ChangYS , SungSI , ParkWS . Mesenchymal stem cells for severe intraventricular hemorrhage in preterm infants: phase I dose-escalation clinical trial. Stem Cells Translational Medicine2018;7(12):847-56. [DOI: 10.1002/sctm.17-0219] [PMID: 30133179]">Ahn 2018</a>; <a href="./references#CD013201-bbs2-0003" title="KotowskiM , LitwinskaZ , KlosP , Pius-SadowskaE , Zagrodnik-UlanE , UstianowskiP , at al. Autologous cord blood transfusion in preterm infants – could its humoral effect be the key to control prematurity-related complications? A preliminary study. Journal of Physiology and Pharmacology2017;68(6):921-7. [PMID: 29550804]">Kotowski 2017</a>; <a href="./references#CD013201-bbs2-0006" title="NCT02274428. Phase 1 clinical trial of PNEUMOSTEM® treatment in premature infants with intraventricular hemorrhage. clinicaltrials.gov/ct2/show/NCT02274428 (first received 24 October 2014). ">NCT02274428</a>; <a href="./references#CD013201-bbs2-0008" title="NCT03696745. The treatment of premature infants with brain injury by autologous umbilical cord blood stem cells. clinicaltrials.gov/show/NCT03696745 (first received 5 October 2018). ">NCT03696745</a>; <a href="./references#CD013201-bbs2-0009" title="YangJ , LuL , LiuZ . Safety of early autologous cord blood cell transfusion for preterms: a descriptive study. Transfusion2018;58:76A-7A. YangJ , RenZ , ZhangC , RaoY , ZhongJ , WangZ , et al. Safety of autologous cord blood cells for preterms: a descriptive study. Stem Cells International2018;2018:5268057. [DOI: 10.1155/2018/5268057] [PMID: 30186329]">Yang 2018</a>), two studied cerebral palsy (<a href="./references#CD013201-bbs2-0005" title="NCT01763255. Multiple transplantation of bone marrow derived CD133 cell in cerebral palsy. clinicaltrials.gov/show/NCT01763255 (first received 8 January 2013). ">NCT01763255</a>; <a href="./references#CD013201-bbs2-0007" title="NCT03087110. Stem cells in umbilical blood infusion for CP. clinicaltrials.gov/ct2/show/NCT03087110 (first received 22 March 2017). ">NCT03087110</a>), one used intratracheal administration (<a href="./references#CD013201-bbs2-0001" title="AhnSY , ChangYS , KimJH , SungSI , ParkWS . Two-year follow-up outcomes of premature infants enrolled in the phase I trial of mesenchymal stem cells transplantation for bronchopulmonary dysplasia. Journal of Pediatrics2017;185:49-54.e2. [DOI: 10.1016/j.jpeds.2017.02.061] [PMID: 28341525]">Ahn 2017</a>), and one was withdrawn (<a href="./references#CD013201-bbs2-0004" title="NCT01121328. Autologous umbilical cord blood transfusion for preterm neonates. clinicaltrials.gov/show/NCT01121328 (first received 12 May 2010). ">NCT01121328</a>) (see <a href="./references#CD013201-sec-0087" title="">Characteristics of excluded studies</a> table). </p> <p><a href="./references#CD013201-bbs2-0001" title="AhnSY , ChangYS , KimJH , SungSI , ParkWS . Two-year follow-up outcomes of premature infants enrolled in the phase I trial of mesenchymal stem cells transplantation for bronchopulmonary dysplasia. Journal of Pediatrics2017;185:49-54.e2. [DOI: 10.1016/j.jpeds.2017.02.061] [PMID: 28341525]">Ahn 2017</a> enrolled nine extremely preterm newborns at high risk of developing BPD. The mean gestational age was 25.3 (SD 0.9) weeks and the mean birth weight was 793 (SD 127) g. All newborns received MSCs intratracheally at a mean age of 10.4 (SD 2.6) days after birth. The first three enrolled infants received MSCs at a low dose (1 × 10<sup>7</sup> cells/kg in 2 mL/kg of saline) and the remaining six newborns received MCSs at a high dose (2 × 10<sup>7</sup> cells/kg in 4 mL/kg of saline). The MCSs were administered in two fractions similarly to surfactant administration. An historical case‐matched comparison group of 14 infants was used. All 9 infants were discharged alive and followed up to 24 months of corrected age. None of the infants required extra oxygen at discharge. One of nine infants died at six months' corrected age due to <i>Enterobacter cloacae</i> sepsis. No adverse events were reported in the remaining eight surviving infants at two years of follow‐up. The mean rehospitalisation rate in the MSC group was 1.4/participant because of respiratory infections during the two‐year follow‐up. The bodyweight growth of the infants in the MSCs group was significantly higher compared to the age‐matched comparison group, while there were no differences in the length/height and head circumference. None of the infants in the MCSs group was diagnosed with cerebral palsy, blindness, hearing deficiency requiring a hearing aid, or developmental delay. </p> <p><a href="./references#CD013201-bbs2-0002" title="AhnSY , ChangYS , SungSI , ParkWS . Mesenchymal stem cells for severe intraventricular hemorrhage in preterm infants: phase I dose-escalation clinical trial. Stem Cells Translational Medicine2018;7(12):847-56. [DOI: 10.1002/sctm.17-0219] [PMID: 30133179]">Ahn 2018</a> enrolled nine newborns (three girls, six boys) with a mean gestational age of 26 weeks (birth weight 440 g to 1310 g at 7 to 15 postnatal days) and diagnosis of severe IVH. The intervention consisted of intraventricular transplantation via an anterior fontanelle tap, using a 24‐gauge catheter guided by cranial ultrasound, and the following sedation with intravenous fentanyl. The first three newborns received a low dose of ex vivo cultured allogeneic, unrelated, human umbilical cord blood‐derived MSCs (5 × 10<sup>6</sup> cells/kg), and the next six received a double dose (1 × 10<sup>7</sup> cells/kg). Transplantation was performed seven days after the diagnosis of IVH. All nine infants had IVH grade 4. No serious adverse effects or dose‐limiting toxicities attributable to MSC transplantation were identified. No infants died during the study period. Five of nine infants required shunt derivation. The follow‐up assessment (two years of age) of these nine preterm infants is ongoing (<a href="./references#CD013201-bbs2-0118" title="NCT02673788. Follow-up study of safety and efficacy of Pneumostem® in premature infants with intraventricular hemorrhage. clinicaltrials.gov/ct2/NCT02673788 (first received 4 February 2016).">NCT02673788</a>). </p> <p><a href="./references#CD013201-bbs2-0003" title="KotowskiM , LitwinskaZ , KlosP , Pius-SadowskaE , Zagrodnik-UlanE , UstianowskiP , at al. Autologous cord blood transfusion in preterm infants – could its humoral effect be the key to control prematurity-related complications? A preliminary study. Journal of Physiology and Pharmacology2017;68(6):921-7. [PMID: 29550804]">Kotowski 2017</a> included preterm newborns (less than 32 weeks' gestational age) who received immediate cord clamping and required blood transfusion for anaemia. The intervention consisted of autologous umbilical cord blood transfusion (five newborns) versus allogeneic red blood cell transfusion (15 newborns). There were no differences in neonatal morbidities (ROP, RDS, NEC); GM‐IVH displayed a trend towards improvement. Umbilical blood infusions appeared to be feasible and without relevant adverse effects, with trends towards hypernatraemia and acidaemia in the autologous cord blood group. A total of 22 plasma proteins were significantly different amongst cord blood recipients compared to controls (i.e. insulin‐like growth factor‐binding protein (IGFBP)‐2, IGFBP‐3, platelet‐derived growth factor A and B (PDGF‐AB), IGF‐1). </p> <p><a href="./references#CD013201-bbs2-0004" title="NCT01121328. Autologous umbilical cord blood transfusion for preterm neonates. clinicaltrials.gov/show/NCT01121328 (first received 12 May 2010). ">NCT01121328</a> was withdrawn (no recruitment). This study was initially designed to test the feasibility of collection, preparation, and infusion of autologous umbilical cord blood in the first 14 days after birth in preterm infants with gestational age less than 35 weeks. The primary outcome was the need for mechanical ventilation during the first month of life. The secondary outcomes were survival until 12 months of age; neurodevelopment at six, 12, and 18 months of age; and postnatal growth. </p> <p><a href="./references#CD013201-bbs2-0005" title="NCT01763255. Multiple transplantation of bone marrow derived CD133 cell in cerebral palsy. clinicaltrials.gov/show/NCT01763255 (first received 8 January 2013). ">NCT01763255</a> is an ongoing RCT with a parallel assignment, which included eight children, aged 4 to 12 years with quadriplegic cerebral palsy. The intervention group children receive an intrathecal injection of bone marrow‐derived CD133 cells and the control children undergo regular follow‐up. The bone marrow‐derived CD133 cells are injected twice: at the diagnosis of quadriplegic cerebral palsy and six months later. The primary outcome is a motor and sensory dysfunction within six months; and unconsciousness and fever within 48 hours post‐transplantation. The secondary outcomes are motor, balance, and spasm improvement within six months. </p> <p><a href="./references#CD013201-bbs2-0006" title="NCT02274428. Phase 1 clinical trial of PNEUMOSTEM® treatment in premature infants with intraventricular hemorrhage. clinicaltrials.gov/ct2/show/NCT02274428 (first received 24 October 2014). ">NCT02274428</a> is an ongoing phase 1 clinical trial on MCSs (Pneumostem) treatment in preterm infants (23 to 34 weeks' gestational age) diagnosed with IVH grade 3 to 4. Nine newborns with a single assignment group are enrolled in the study. All infants are included within seven days after the diagnosis of IVH grade 3 to 4. The route of administration and the dose of MCSs are not reported. The primary outcome of the study is unexpected death or anaphylactic shock within six hours after MCSs transplantation; the secondary outcome is death or hydrocephalus requiring shunt operation at first discharge up to one year after birth. </p> <p><a href="./references#CD013201-bbs2-0007" title="NCT03087110. Stem cells in umbilical blood infusion for CP. clinicaltrials.gov/ct2/show/NCT03087110 (first received 22 March 2017). ">NCT03087110</a> is an ongoing study of a single intravenous infusion of cord blood cells (greater than 1 × 10<sup>7</sup> cells/kg) of matched sibling donor to a child diagnosed with any type of cerebral palsy. Twelve children aged one to 16 years are enrolled in a single group assignment study. The primary outcome is safety, defined by the number of participants with abnormal clinical assessment or laboratory values (or both) within 12 months. The secondary outcomes are changes in motor and cognitive functions at three months, changes in quality of life at 12 months, and detection of circulating fraction of donor's DNA at three months. </p> <p><a href="./references#CD013201-bbs2-0008" title="NCT03696745. The treatment of premature infants with brain injury by autologous umbilical cord blood stem cells. clinicaltrials.gov/show/NCT03696745 (first received 5 October 2018). ">NCT03696745</a> is an ongoing non‐randomised open‐label clinical trial that recruiting newborns born between 28 and greater than 37 weeks affected by hypoxic‐ischaemic encephalopathy. It is planned to recruit 200 newborns, and they will be assigned either to the intervention group (receiving autologous umbilical cord blood stem cells at 5 × 10<sup>7</sup> cells/kg; up to four infusions), or to the placebo group (0.9% sodium chloride). The primary outcome is safety, defined as the rate of adverse events during and within 24 months of infusion. The secondary outcome is neurodevelopmental function at four to six months and nine to 12 months of age. </p> <p><a href="./references#CD013201-bbs2-0009" title="YangJ , LuL , LiuZ . Safety of early autologous cord blood cell transfusion for preterms: a descriptive study. Transfusion2018;58:76A-7A. YangJ , RenZ , ZhangC , RaoY , ZhongJ , WangZ , et al. Safety of autologous cord blood cells for preterms: a descriptive study. Stem Cells International2018;2018:5268057. [DOI: 10.1155/2018/5268057] [PMID: 30186329]">Yang 2018</a> enrolled preterm newborns (none less than 28 weeks). Autologous volume and red blood cells reduced non‐cryopreserved umbilical cord blood infusion by 5 × 10<sup>7</sup> cells/kg. The sample included 15 newborns (28+2 to 34+1 weeks). All survived, and there was no significant change in safety measures after infusion. </p> </section> <section id="CD013201-sec-0048"> <h4 class="title">Ongoing studies</h4> <p>We identified three relevant studies on the clinical trials registries for ongoing or recently completed trials (<a href="./references#CD013201-bbs2-0010" title="ACTRN12619001637134. Autologous transplantation of umbilical cord blood derived stem cells in extreme preterm infants: protocol for a safety and feasibility study. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=378721 (first received 11 November 2019). [ACTRN: 12619001637134] MalhotraA , NovakI , MillerSL , JenkinG . Autologous transplantation of umbilical cord blood-derived cells in extreme preterm infants: protocol for a safety and feasibility study. BMJ Open2020;10(5):e036065. [DOI: 10.1136/bmjopen-2019-036065] [PMID: 32398336]">ACTRN12619001637134</a>; <a href="./references#CD013201-bbs2-0011" title="NCT02890953. Efficacy and safety evaluation of Pneumostem® versus a control group for treatment of IVH in premature infants (phase 2a). clinicaltrials.gov/ct2/show/NCT02890953 (first received 7 September 2016). ">NCT02890953</a>; <a href="./references#CD013201-bbs2-0012" title="NCT04440670. Effect of autologous cord blood mononuclear cells for prevention of bronchopulmonary dysplasia in extremely preterm neonates: a placebo-controlled randomized multicenter trial. clinicaltrials.gov/show/NCT04440670 (first received 22 June 2020). ">NCT04440670</a>). On 25 March 2022, we contacted the study authors to request an update on the recruitment status of the infants. See <a href="./references#CD013201-sec-0088" title="">Characteristics of ongoing studies</a> table. </p> <p><a href="./references#CD013201-bbs2-0010" title="ACTRN12619001637134. Autologous transplantation of umbilical cord blood derived stem cells in extreme preterm infants: protocol for a safety and feasibility study. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=378721 (first received 11 November 2019). [ACTRN: 12619001637134] MalhotraA , NovakI , MillerSL , JenkinG . Autologous transplantation of umbilical cord blood-derived cells in extreme preterm infants: protocol for a safety and feasibility study. BMJ Open2020;10(5):e036065. [DOI: 10.1136/bmjopen-2019-036065] [PMID: 32398336]">ACTRN12619001637134</a> is single‐centre safety and feasibility study on extremely preterm infants (i.e. born before 28 weeks' gestation). Autologous via the intravenous route at a dose of 25 to 50 million MNCs/kg bodyweight of live cells are administered. Primary outcomes are feasibility ("access to sufficient cord blood at collection and MNCs following processing") and safety ("adverse events directly related to autologous MNCs administration in the first few days after cell administration"). Secondary outcomes include neurodevelopmental outcome, cord blood cell characteristics, and cytokine responses to cell administration in transplanted infants to 36 weeks' corrected age. Dr Malhotra replied that nearly half of participants are recruited (planned sample size: 20 preterm infants); likely to be completed by the end of 2022/early 2023. </p> <p><a href="./references#CD013201-bbs2-0011" title="NCT02890953. Efficacy and safety evaluation of Pneumostem® versus a control group for treatment of IVH in premature infants (phase 2a). clinicaltrials.gov/ct2/show/NCT02890953 (first received 7 September 2016). ">NCT02890953</a> is a phase 2 RCT that is planning to recruit 22 preterm infants with gestational age 23 to 34 weeks, postnatal age within 28 days, and IVH grade 3 to 4. Exclusion criteria include newborns with severe congenital abnormalities; antenatal brain haemorrhage; asphyxia or hypoxic‐ischaemic encephalopathy; chromosome anomalies; severe congenital malformation; concurrent severe congenital infection; C‐reactive protein greater than 30 mg/dL; severe sepsis or shock; severe IVH; and history of participating in other clinical trials. Infants will be randomised to direct intracerebroventricular injection of either MSCs (Pneumostem) or normal saline. The primary outcome will be death or shunt operation; secondary outcomes will include volume ratio of ventricle to whole brain on brain MRI and death. </p> <p><a href="./references#CD013201-bbs2-0012" title="NCT04440670. Effect of autologous cord blood mononuclear cells for prevention of bronchopulmonary dysplasia in extremely preterm neonates: a placebo-controlled randomized multicenter trial. clinicaltrials.gov/show/NCT04440670 (first received 22 June 2020). ">NCT04440670</a> is a multicentre RCT enrolling 200 extremely preterm infants, randomised to either intravenous autologous cord blood MNCs infusion (5 × 10<sup>7</sup> cells/kg) or placebo (normal saline) within 24 hours after birth. The primary outcome is survival without BPM at 36 weeks of postmenstrual age or discharge home; the secondary outcomes include mortality rate, another common preterm complication rate, respiratory support duration, the length and cost of hospitalisation, and long‐term outcomes after two years' follow‐up postinfusion. </p> <section id="CD013201-sec-0049"> <h5 class="title">Studies in other neonatal populations</h5> <p>The use of stem cell‐based interventions for hypoxic‐ischaemic encephalopathy and BPD is reported in other Cochrane Reviews (<a href="./references#CD013201-bbs2-0036" title="BruschettiniM , RomantsikO , MoreiraA , LeyD , ThébaudB . Stem cell-based interventions for the prevention of morbidity and mortality following hypoxic-ischaemic encephalopathy in newborn infants. Cochrane Database of Systematic Reviews2020, Issue 8. Art. No: CD013202. [DOI: 10.1002/14651858.CD013202.pub2] [PMID: 32813884]">Bruschettini 2020</a>; <a href="./references#CD013201-bbs2-0144" title="PierroM , ThebaudB , SollR . Mesenchymal stem cells for the prevention and treatment of bronchopulmonary dysplasia in preterm infants. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD011932. [DOI: 10.1002/14651858.CD011932.pub2]">Pierro 2017</a>). </p> </section> </section> </section> <section id="CD013201-sec-0050"> <h3 class="title">Risk of bias in included studies</h3> <p>No study met the eligibility criteria of this review.</p> <section id="CD013201-sec-0051"> <h4 class="title">Allocation</h4> <p>No study met the eligibility criteria of this review.</p> </section> <section id="CD013201-sec-0052"> <h4 class="title">Blinding</h4> <p>No study met the eligibility criteria of this review.</p> </section> <section id="CD013201-sec-0053"> <h4 class="title">Incomplete outcome data</h4> <p>No study met the eligibility criteria of this review.</p> </section> <section id="CD013201-sec-0054"> <h4 class="title">Selective reporting</h4> <p>No study met the eligibility criteria of this review.</p> </section> <section id="CD013201-sec-0055"> <h4 class="title">Other potential sources of bias</h4> <p>No study met the eligibility criteria of this review.</p> </section> </section> <section id="CD013201-sec-0056"> <h3 class="title" id="CD013201-sec-0056">Effects of interventions</h3> <p>No study met the eligibility criteria of this review.</p> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013201-sec-0057" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013201-sec-0057"></div> <section id="CD013201-sec-0058"> <h3 class="title" id="CD013201-sec-0058">Summary of main results</h3> <p>We found no published RCTs or quasi‐RCTs addressing the benefits or harms of stem cell‐based therapies for prevention or treatment of GM‐IVH and EoP in preterm infants. </p> <p>We identified three ongoing studies, with a sample size range from 20 to 200. In two studies, autologous cord blood MNCs will be administered to extremely preterm infants via the intravenous route (<a href="./references#CD013201-bbs2-0010" title="ACTRN12619001637134. Autologous transplantation of umbilical cord blood derived stem cells in extreme preterm infants: protocol for a safety and feasibility study. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=378721 (first received 11 November 2019). [ACTRN: 12619001637134] MalhotraA , NovakI , MillerSL , JenkinG . Autologous transplantation of umbilical cord blood-derived cells in extreme preterm infants: protocol for a safety and feasibility study. BMJ Open2020;10(5):e036065. [DOI: 10.1136/bmjopen-2019-036065] [PMID: 32398336]">ACTRN12619001637134</a>; <a href="./references#CD013201-bbs2-0012" title="NCT04440670. Effect of autologous cord blood mononuclear cells for prevention of bronchopulmonary dysplasia in extremely preterm neonates: a placebo-controlled randomized multicenter trial. clinicaltrials.gov/show/NCT04440670 (first received 22 June 2020). ">NCT04440670</a>); in one, intracerebroventricular injection of MSCs will be administered to preterm infants up to 34 weeks' gestational age (<a href="./references#CD013201-bbs2-0011" title="NCT02890953. Efficacy and safety evaluation of Pneumostem® versus a control group for treatment of IVH in premature infants (phase 2a). clinicaltrials.gov/ct2/show/NCT02890953 (first received 7 September 2016). ">NCT02890953</a>). </p> </section> <section id="CD013201-sec-0059"> <h3 class="title" id="CD013201-sec-0059">Overall completeness and applicability of evidence</h3> <p>The first trial on the use of MSCs for GM‐IVH took place in South Korea and was published in 2018 (<a href="./references#CD013201-bbs2-0002" title="AhnSY , ChangYS , SungSI , ParkWS . Mesenchymal stem cells for severe intraventricular hemorrhage in preterm infants: phase I dose-escalation clinical trial. Stem Cells Translational Medicine2018;7(12):847-56. [DOI: 10.1002/sctm.17-0219] [PMID: 30133179]">Ahn 2018</a>). This phase 1 dose‐escalation trial demonstrated the safety and feasibility of a single intraventricular transplantation (5 × 10<sup>6</sup> cells/kg, 1 × 10<sup>7</sup> cells/kg) of umbilical cord blood‐derived MSCs in preterm neonates with a diagnosis of severe GM‐IVH (three per Papile's classification or greater; <a href="./references#CD013201-bbs2-0132" title="PapileLA , BursteinJ , BursteinR , KofflerH . Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. Journal of Pediatrics1978;92(4):529-34. [PMID: 305471]">Papile 1978</a>). Nine neonates were treated within seven days after diagnosis of a severe GM‐IVH, for whom study authors reported no serious adverse events or dose‐limiting toxicities secondary to MSC transplantation. We did not include this study in our review because it is a phase 1 trial. Long‐term follow‐up is currently ongoing (<a href="./references#CD013201-bbs2-0011" title="NCT02890953. Efficacy and safety evaluation of Pneumostem® versus a control group for treatment of IVH in premature infants (phase 2a). clinicaltrials.gov/ct2/show/NCT02890953 (first received 7 September 2016). ">NCT02890953</a>). This group of investigators was the first to demonstrate the safety and feasibility of MSCs for preterm lung disease (<a href="./references#CD013201-bbs2-0039" title="ChangYS , AhnSY , YooHS , SungSI , ChoiSJ , OhWI , et al. Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. Journal of Pediatrics2014;164(5):966-72.e6. [DOI: 10.1016/j.jpeds.2013.12.011] [PMID: 24508444]">Chang 2014</a>); this group is planning a phase 2 trial of MSCs for BPD (<a href="./references#CD013201-bbs2-0121" title="NCT03392467. PNEUMOSTEM for the prevention and treatment of severe BPD in premature infants. clinicaltrials.gov/ct2/show/NCT03392467 (first received 8 January 2018).">NCT03392467</a>), and is recruiting for the phase 2 trial of MSCs for GM‐IVH. Of note, the feasibility of collecting umbilical cord blood in a sample of 141 newborn infants at risk of brain damage has been reported (<a href="./references#CD013201-bbs2-0160" title="SeglerA , BraunT , FischerHS , DukatzR , WeissCR , SchwickertA , et al. Feasibility of umbilical cord blood collection in neonates at risk of brain damage – a step toward autologous cell therapy for a high-risk population. Cell Transplantation2021;30:963689721992065. [DOI: 10.1177/0963689721992065] [PMID: 33631961]">Segler 2021</a>). </p> <p>Currently, no effective therapies for GM‐IVH or EoP are available. Cell‐based therapies are significant contenders for treatment, given that these agents are equipped with paracrine factors that can act on the multifactorial mechanisms implicated in brain injury. Collectively, the secretion of BDNF, VEGF, hepatocyte growth factor, and immunomodulatory cytokines from regenerative cells enhances nerve remyelination, improves neuronal survival, and reduces neuroinflammation (<a href="#CD013201-tbl-0001">Table 1</a>). Although exciting progress has been noted in animal studies, successful translation into the clinic requires improved understanding of key fundamental questions in stem cell biology. </p> </section> <section id="CD013201-sec-0060"> <h3 class="title" id="CD013201-sec-0060">Quality of the evidence</h3> <p>We identified no trials for inclusion.</p> </section> <section id="CD013201-sec-0061"> <h3 class="title" id="CD013201-sec-0061">Potential biases in the review process</h3> <p>We used the standard methods of Cochrane Neonatal in conducting this systematic review. It is unlikely that the literature search applied to this review may have missed relevant trials, thus we are confident that this systematic review summarises all the presently available RCT evidence on stem cell‐based interventions for GM‐IVH and EoP in preterm infants. We applied no language restrictions. </p> </section> <section id="CD013201-sec-0062"> <h3 class="title" id="CD013201-sec-0062">Agreements and disagreements with other studies or reviews</h3> <p>The use of stem cell‐based interventions for hypoxic‐ischaemic encephalopathy (<a href="./references#CD013201-bbs2-0036" title="BruschettiniM , RomantsikO , MoreiraA , LeyD , ThébaudB . Stem cell-based interventions for the prevention of morbidity and mortality following hypoxic-ischaemic encephalopathy in newborn infants. Cochrane Database of Systematic Reviews2020, Issue 8. Art. No: CD013202. [DOI: 10.1002/14651858.CD013202.pub2] [PMID: 32813884]">Bruschettini 2020</a>), and BPD (<a href="./references#CD013201-bbs2-0144" title="PierroM , ThebaudB , SollR . Mesenchymal stem cells for the prevention and treatment of bronchopulmonary dysplasia in preterm infants. Cochrane Database of Systematic Reviews2017, Issue 11. Art. No: CD011932. [DOI: 10.1002/14651858.CD011932.pub2]">Pierro 2017</a>), is reported in other Cochrane Reviews. This is the first systematic review of clinical studies on stem cell‐based interventions for GM‐IVH or EoP. One narrative review has highlighted the need of well‐conducted preclinical studies to explore the effects of stem cell‐based interventions in a model of preterm birth (<a href="./references#CD013201-bbs2-0170" title="ThébaudB . Stem cells for extreme prematurity. American Journal of Perinatology2019;36(S02):68-73. [DOI: 10.1055/s-0039-1691774] [PMID: 31238363]">Thébaud 2019</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013201-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013201.pub3/media/CDSR/CD013201/urn:x-wiley:14651858:media:CD013201:CD013201-FIG-01" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD013201-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013201.pub3/media/CDSR/CD013201/image_n/nCD013201-FIG-01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013201.pub3/media/CDSR/CD013201/image_t/tCD013201-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013201.pub3/full#CD013201-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013201.pub3/media/CDSR/CD013201/image_n/nCD013201-FIG-01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD013201-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Types of regenerative cells</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Cell type</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Source</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Rationale</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Mechanism of action</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Preclinical/clinical results</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>References</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Human umbilical cord tissue/blood; rodent/human bone marrow</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Safe and feasible in phase 1 RCT for bronchopulmonary dysplasia</p> <p> <ul id="CD013201-list-0001"> <li> <p>Low immunogenicity (low MHC II), easily obtainable, rapid expansion</p> </li> <li> <p>Autologous/allogeneic administration</p> </li> <li> <p>Paracrine release of trophic factors</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0002"> <li> <p>Paracrine release of IGF‐1, EGF, VEGF, BDNF</p> </li> <li> <p>Immunomodulatory: regulate T‐cell, B‐cell function, and production of inflammatory cytokines </p> </li> <li> <p>Mitochondrial transfer</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0003"> <li> <p>Nerve fibre remyelination and axonal regeneration; improve behavioural/motor tests</p> </li> <li> <p>Enhance neural cell proliferation, survival, function</p> </li> <li> <p>Decrease infarct size</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013201-bbs2-0015" title="AhnSY , ChangYS , ParkWS . Stem cells for neonatal brain disorders. Neonatology2016;109(4):377-83. [PMID: 27251746]">Ahn 2016</a>; <a href="./references#CD013201-bbs2-0034" title="BoshuizenMC , SteinbergGK . Stem cell-based immunomodulation after stroke: effects on brain repair processes. Stroke2018;49(6):1563-70. [PMID: 29724892]">Boshuizen 2018</a>; <a href="./references#CD013201-bbs2-0042" title="ChoppM , LiY . Treatment of neural injury with marrow stromal cells. Lancet Neurology2002;1(2):92-100. [PMID: 12849513]">Chopp 2002</a>; <a href="./references#CD013201-bbs2-0075" title="HsuYC , WuYT , YuTH , WeiYH . Mitochondria in mesenchymal stem cell biology and cell therapy: from cellular differentiation to mitochondrial transfer. Seminars in Cell &amp; Developmental Biology2016;52:119-31. [DOI: 10.1016/j.semcdb.2016.02.011] [PMID: 26868759]">Hsu 2016</a>; <a href="./references#CD013201-bbs2-0080" title="IslamMN , DasSR , EminMT , WeiM , SunL , WestphalenK , et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nature Medicine2012;18(5):759-65. [DOI: 10.1038/nm.2736] [PMID: 22504485]">Islam 2012</a>; <a href="./references#CD013201-bbs2-0098" title="LiuAM , LuG , TsangKS , LiG , WuY , HuangZS , et al. Umbilical cord-derived mesenchymal stem cells with forced expression of hepatocyte growth factor enhance remyelination and functional recovery in a rat intracerebral hemorrhage model. Neurosurgery2010;67(2):357-65; discussion 365-6. [DOI: 10.1227/01.NEU.0000371983.06278.B3] [PMID: 20644422]">Liu 2010</a>; <a href="./references#CD013201-bbs2-0113" title="MurphyMB , MoncivaisK , CaplanAI . Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Experimental &amp; Molecular Medicine2013;45(11):e54. [DOI: 10.1038/emm.2013.94] [PMID: 24232253]">Murphy 2013</a>; <a href="./references#CD013201-bbs2-0133" title="ParkWS , SungSI , AhnSY , SungDK , ImGH , YooHS , et al. Optimal timing of mesenchymal stem cell therapy for neonatal intraventricular hemorrhage. Cell Transplantation2016;25(6):1131-44. [DOI: 10.3727/096368915X689640] [PMID: 26440762]">Park 2016</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>MNC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Human umbilical cord blood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0004"> <li> <p>Readily collected and large supply in cord blood with high plasticity</p> </li> <li> <p>Safe and feasible in phase 1 RCT for hypoxic‐ischaemic encephalopathy</p> </li> <li> <p>Low immunogenicity (minimal HLA matching)</p> </li> <li> <p>Paracrine release of trophic factors</p> </li> <li> <p>Autologous/allogeneic administration</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0005"> <li> <p>Increase expression of BDNF, NGF, VEGF, GDNF</p> </li> <li> <p>Activate prosurvival Akt pathway</p> </li> <li> <p>Decrease TNF‐α and increase IL‐10 gene expression</p> </li> <li> <p>Reduce CD4+ T‐cell infiltration</p> </li> <li> <p>Regulate hedgehog signalling</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0006"> <li> <p>Decrease neuronal apoptosis, astrogliosis, inflammation</p> </li> <li> <p>Improve oligodendrocyte survival; induce axonal growth</p> </li> <li> <p>Improve neurobehavioural outcomes</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013201-bbs2-0019" title="AridasJD , McDonaldCA , PatonMC , YawnoT , SutherlandAE , NitsosI , et al. Cord blood mononuclear cells prevent neuronal apoptosis in response to perinatal asphyxia in the newborn lamb. Journal of Physiology2016;594(5):1421-35. [DOI: 10.1113/JP271104] [PMID: 26527561]">Aridas 2016</a>; <a href="./references#CD013201-bbs2-0045" title="CottenCM , MurthaAP , GoldbergRN , GrotegutCA , SmithPB , GoldsteinRF , et al. Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy. Journal of Pediatrics2014;164(5):973-9.e1. [DOI: 10.1016/j.jpeds.2013.11.036] [PMID: 24388332]">Cotten 2014</a>; <a href="./references#CD013201-bbs2-0057" title="FanCG , ZhangQJ , TangFW , HanZB , WangGS , HanZC . Human umbilical cord blood cells express neurotrophic factors. Neuroscience Letters2005;380(3):322-5. [DOI: 10.1016/j.neulet.2005.01.070] [PMID: 15862910]">Fan 2005</a>; <a href="./references#CD013201-bbs2-0104" title="McDonaldCA , PennyTR , PatonMC , SutherlandAE , NekkantiL , YawnoT , et al. Effects of umbilical cord blood cells, and subtypes, to reduce neuroinflammation following perinatal hypoxic-ischemic brain injury. Journal of Neuroinflammation2018;15(1):47. [PMID: 29454374]">McDonald 2018</a>; <a href="./references#CD013201-bbs2-0145" title="Pimentel-CoelhoPM , Rosado-de-CastroPH , da FonsecaLM , Mendez-OteroR . Umbilical cord blood mononuclear cell transplantation for neonatal hypoxic-ischemic encephalopathy. Pediatric Research2012;71(4 Pt 2):464-73. [DOI: 10.1038/pr.2011.59] [PMID: 22430382]">Pimentel‐Coelho 2012</a>; <a href="./references#CD013201-bbs2-0153" title="RoweDD , LeonardoCC , HallAA , ShahaduzzamanMD , CollierLA , WillingAE , et al. Cord blood administration induces oligodendrocyte survival through alterations in gene expression. Brain Research2010;1366:172-88. [DOI: 10.1016/j.brainres.2010.09.078] [PMID: 20883670]">Rowe 2010</a>; <a href="./references#CD013201-bbs2-0189" title="WangXL , ZhaoYS , HuMY , SunYQ , ChenYX , BiXH . Umbilical cord blood cells regulate endogenous neural stem cell proliferation via hedgehog signaling in hypoxic ischemic neonatal rats. Brain Research2013;1518:26-35. [DOI: 10.1016/j.brainres.2013.04.038] [PMID: 23632377]">Wang 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OPC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rodent/human ESC; human NSC derivation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0007"> <li> <p>Differentiate into oligodendrocytes (cells highly susceptible to hypoxic‐ischaemic injury) </p> </li> <li> <p>Remyelinate injured axons</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0008"> <li> <p>Diffuse biodistribution along white matter tracts and differentiate into myelin sheath‐producing oligodendrocytes </p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0009"> <li> <p>Promote myelin sheath formation and NSC proliferation, inhibit apoptosis</p> </li> <li> <p>Motor recovery following CNS injury</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013201-bbs2-0041" title="ChenLX , MaSM , ZhangP , FanZC , XiongM , ChengGQ , et al. Neuroprotective effects of oligodendrocyte progenitor cell transplantation in premature rat brain following hypoxic-ischemic injury. PLOS One2015;10(3):e0115997. [PMID: 25790286]">Chen 2015</a>; <a href="./references#CD013201-bbs2-0064" title="GopagondanahalliKR , LiJ , FaheyMC , HuntRW , JenkinG , MillerSL , et al. Preterm hypoxic-ischemic encephalopathy. Frontiers in Pediatrics2016;4:114. [DOI: 10.3389/fped.2016.00114] [PMID: 27812521]">Gopagondanahalli 2016</a>; <a href="./references#CD013201-bbs2-0088" title="KimTK , ParkD , BanYH , ChaY , AnES , ChoiJ , et al. Improvement by human oligodendrocyte progenitor cells of neurobehavioral disorders in an experimental model of neonatal periventricular leukomalacia. Cell Transplantation2018;27(7):1168-77. [DOI: 10.1177/0963689718781330] [PMID: 29978719]">Kim 2018</a>; <a href="./references#CD013201-bbs2-0102" title="ManleyNC , PriestCA , DenhamJ , Wirth ED 3rd, LebkowskiJS . Human embryonic stem cell-derived oligodendrocyte progenitor cells: preclinical efficacy and safety in cervical spinal cord injury. Stem Cells Translational Medicine2017;6(10):1917-29. [DOI: 10.1002/sctm.17-0065] [PMID: 28834391]">Manley 2017</a>; <a href="./references#CD013201-bbs2-0123" title="NiimiY , LevisonSW . Pediatric brain repair from endogenous neural stem cells of the subventricular zone. Pediatric Research2018;83(1-2):385-96. [DOI: 10.1038/pr.2017.261] [PMID: 29028220]">Niimi 2018</a>; <a href="./references#CD013201-bbs2-0193" title="XuL , RyuJ , HielH , MenonA , AggarwalA , RhaE , et al. Transplantation of human oligodendrocyte progenitor cells in an animal model of diffuse traumatic axonal injury: survival and differentiation. Stem Cell Research &amp; Therapy2015;6:93. [DOI: 10.1186/s13287-015-0087-0] [PMID: 25971252]">Xu 2015</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Human foetal striatum; human ESC; human iPSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0010"> <li> <p>Differentiate into cells necessary for brain repair, including neurons, astrocytes, and oligodendrocytes </p> </li> <li> <p>Paracrine release of trophic factors</p> </li> <li> <p>Low immunogenicity and tumorigenicity</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0011"> <li> <p>Immunomodulation</p> </li> <li> <p>Paracrine secretion of BDNF, VEGF, and EGF</p> </li> <li> <p>Attenuate NF‐κB signalling</p> </li> <li> <p>Upregulate glutamate transport</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD013201-list-0012"> <li> <p>Stimulate survival and migration of endogenous NSCs and neurons</p> </li> <li> <p>Reduce inflammation and reactive oxygen species production</p> </li> <li> <p>Improve axonal growth, motor function; decrease infarct size</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013201-bbs2-0047" title="DaadiMM , KlausnerJQ , BajarB , GoshenI , Lee-MesserC , LeeSY , et al. Optogenetic stimulation of neural grafts enhances neurotransmission and downregulates the inflammatory response in experimental stroke model. Cell Transplantation2016;25(7):1371-80. [DOI: 10.3727/096368915X688533] [PMID: 26132738]">Daadi 2016</a>; <a href="./references#CD013201-bbs2-0076" title="HuangL , ZhangL . Neural stem cell therapies and hypoxic-ischemic brain injury. Progress in Neurobiology2018;173:1-17. [DOI: 10.1016/j.pneurobio.2018.05.004] [PMID: 29758244]">Huang 2018</a>; <a href="./references#CD013201-bbs2-0084" title="JiG , LiuM , ZhaoXF , LiuXY , GuoQL , GuanZF , et al. NF-kappaB signaling is involved in the effects of intranasally engrafted human neural stem cells on neurofunctional improvements in neonatal rat hypoxic-ischemic encephalopathy. CNS Neuroscience &amp; Therapeutics2015;21(12):926-35. [DOI: 10.1111/cns.12441] [PMID: 26255634]">Ji 2015</a>; <a href="./references#CD013201-bbs2-0106" title="MineY , TatarishviliJ , OkiK , MonniE , KokaiaZ , LindvallO . Grafted human neural stem cells enhance several steps of endogenous neurogenesis and improve behavioral recovery after middle cerebral artery occlusion in rats. Neurobiology of Disease2013;52:191-203. [DOI: 10.1016/j.nbd.2012.12.006] [PMID: 23276704]">Mine 2013</a> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Umbilical cord blood</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0013"> <li> <p>Paracrine release of neurotrophic factors</p> </li> <li> <p>Multipotent capacity and ability to transdifferentiate into neuronal cells</p> </li> <li> <p>Autologous/allogeneic administration</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0014"> <li> <p>Reduce microglial cells and T lymphocytes</p> </li> <li> <p>Secrete VEGF, HGF, IGF‐1</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD013201-list-0015"> <li> <p>Decrease infarct size and maintain cerebral blood flow</p> </li> <li> <p>Enhance axonal growth</p> </li> <li> <p>Ameliorate neuronal apoptosis and postischaemic inflammation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013201-bbs2-0159" title="SchwartingS , LitwakS , HaoW , BahrM , WeiseJ , NeumannH . Hematopoietic stem cells reduce postischemic inflammation and ameliorate ischemic brain injury. Stroke2008;39(10):2867-75. [DOI: 10.1161/STROKEAHA.108.513978] [PMID: 18658037]">Schwarting 2008</a>; <a href="./references#CD013201-bbs2-0174" title="TsujiM , TaguchiA , OhshimaM , KasaharaY , SatoY , TsudaH , et al. Effects of intravenous administration of umbilical cord blood CD34(+) cells in a mouse model of neonatal stroke. Neuroscience2014;263:148-58. [PMID: 24444827]">Tsuji 2014</a>; <a href="./references#CD013201-bbs2-0181" title="VerinaT , FatemiA , JohnstonMV , ComiAM . Pluripotent possibilities: human umbilical cord blood cell treatment after neonatal brain injury. Pediatric Neurology2013;48(5):346-54. [DOI: 10.1016/j.pediatrneurol.2012.10.010] [PMID: 23583051]">Verina 2013</a> </p> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>iPSC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Skin fibroblasts, umbilical cord tissue, amniotic tissue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0016"> <li> <p>Autologous administration</p> </li> <li> <p>Differentiation into multiple neural lineage cells</p> </li> <li> <p>Low immunogenicity</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> <ul id="CD013201-list-0017"> <li> <p>Differentiate into functional neural cells (electrophysiological properties)</p> </li> <li> <p>Decrease infiltration of MPO+ neutrophils and CD11b+ microglia</p> </li> <li> <p>VEGF expression and organelle transfer</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> <ul id="CD013201-list-0018"> <li> <p>Improve survival and sensorimotor function</p> </li> <li> <p>Establish axonal connections</p> </li> <li> <p>Inhibit inflammation, neural apoptosis, and glial scar formation</p> </li> </ul> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013201-bbs2-0037" title="CaiJ , LiW , SuH , QinD , YangJ , ZhuF , et al. Generation of human induced pluripotent stem cells from umbilical cord matrix and amniotic membrane mesenchymal cells. Journal of Biological Chemistry2010;285(15):11227-34. [DOI: 10.1074/jbc.M109.086389] [PMID: 20139068]">Cai 2010</a>; <a href="./references#CD013201-bbs2-0075" title="HsuYC , WuYT , YuTH , WeiYH . Mitochondria in mesenchymal stem cell biology and cell therapy: from cellular differentiation to mitochondrial transfer. Seminars in Cell &amp; Developmental Biology2016;52:119-31. [DOI: 10.1016/j.semcdb.2016.02.011] [PMID: 26868759]">Hsu 2016</a>; <a href="./references#CD013201-bbs2-0128" title="OkiK , TatarishviliJ , WoodJ , KochP , WattananitS , MineY , et al. Human-induced pluripotent stem cells form functional neurons and improve recovery after grafting in stroke-damaged brain. Stem Cells2012;30(6):1120-33. [DOI: 10.1002/stem.1104] [PMID: 22495829]">Oki 2012</a>; <a href="./references#CD013201-bbs2-0146" title="PluchinoS , Peruzzotti-JamettiL . Rewiring the ischaemic brain with human-induced pluripotent stem cell-derived cortical neurons. Brain2013;136(Pt 12):3525-7. [PMID: 24335051]">Pluchino 2013</a>; <a href="./references#CD013201-bbs2-0148" title="QinJ , MaX , QiH , SongB , WangY , WenX , et al. Transplantation of induced pluripotent stem cells alleviates cerebral inflammation and neural damage in hemorrhagic stroke. PLOS One2015;10(6):e0129881. [PMID: 26086994]">Qin 2015</a>; <a href="./references#CD013201-bbs2-0171" title="TorneroD , WattananitS , Gronning MadsenM , KochP , WoodJ , TatarishviliJ , et al. Human induced pluripotent stem cell-derived cortical neurons integrate in stroke-injured cortex and improve functional recovery. Brain2013;136(Pt 12):3561-77. [DOI: 10.1093/brain/awt278] [PMID: 24148272]">Tornero 2013</a> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>BDNF: brain‐derived neurotrophic factor; CNS: central nervous system; EGF: epidermal growth factor; ESC: embryonic stem cell; GDNF: glial cell‐line‐derived neurotrophic factor; HGF: hepatocyte growth factor; HLA: human leukocyte antigen; HSC: haematopoietic stem cell; IGF‐1: insulin‐like growth factor‐1; IL: interleukin; iPSC: inducible pluripotent stem cell; MHC: major histocompatibility complex; MNC: mononuclear cell; MSC: mesenchymal stem cell; NF‐κB: nuclear factor kappa beta; NGF: nerve growth factor; NSC: neural stem cell; OPC: oligodendrocyte progenitor cell; RCT: randomised controlled trial; TNF: tumour necrosis factor; VEGF: vascular endothelial growth factor. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Types of regenerative cells</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013201.pub3/full#CD013201-tbl-0001">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013201.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013201-note-0012">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013201-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013201-note-0011">Français</a> </li> <li class="section-language"> <a class="" href="id#CD013201-note-0009">Bahasa Indonesia</a> </li> <li class="section-language"> <a class="" href="ko#CD013201-note-0005">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD013201-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD013201-note-0010">Polski</a> </li> <li class="section-language"> <a class="" href="th#CD013201-note-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013201-note-0004">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"/> </img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013201\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013201\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013201\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013201\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013201\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013201\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013201\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013201\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013201\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013201\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013201\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013201\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013201\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013201\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013201\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013201\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013201\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013201\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=BqmVIxTs&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013201.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013201.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013201.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013201.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013201.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725155743"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013201.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725155749"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013201.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e7453fb551be5',t:'MTc0MDcyNTE1Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 